

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Recent therapeutic advances in chronic... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/6-1924/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/6-1924" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Recent therapeutic advances in chronic lymphocytic leukemia" />
    
            <meta name="og:title" content="F1000Research Article: Recent therapeutic advances in chronic lymphocytic leukemia.">
            <meta name="og:description" content="Read the latest article version by Prithviraj Bose, Varsha Gandhi, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="12549">
            <meta name="article-id" content="11618">
            <meta name="dc.title" content="Recent therapeutic advances in chronic lymphocytic leukemia">
            <meta name="dc.description" content="The last several years have witnessed a paradigm shift in the management of patients with chronic lymphocytic leukemia (CLL). The course of this very heterogeneous disease, traditionally treated with chemotherapeutic agents usually in combination with rituximab, typically has been characterized by remissions and relapses, and survival times vary greatly, depending on intrinsic biological attributes of the leukemia. The developments of the last few years have been transformative, ushering in an era of novel, molecularly targeted therapies, made possible by extensive efforts to elucidate the biology of the disease that predated the new targeted drugs. Thus, successful therapeutic targeting of the B-cell receptor signaling pathway and of the Bcl-2 anti-apoptotic protein with small molecules has now made chemotherapy-free approaches possible, hopefully mitigating the risk of development of therapy-related myeloid neoplasms and making eventual cure of CLL with the use of optimal drug combinations a realistic goal. Most importantly, these therapies have demonstrated unprecedented efficacy in patients with deletion 17p/TP53 mutation, a subset that historically has been very difficult to treat. However, as we gain more experience with the newer agents, unique safety concerns and resistance mechanisms have emerged, as has the issue of cost, as these expensive drugs are currently administered indefinitely. Accordingly, novel laboratory-based strategies and clinical trial designs are being explored to address these issues. The availability of whole exome/genome sequencing has given us profound insights into the mutational landscape of CLL. In this article, we highlight some of the most impactful advances since this topic was last reviewed in this journal.">
            <meta name="dc.subject" content="CLL, BCR pathway, ibrutinib, BTK, Bcl-2, venetoclax, CD20 antibody, PI3K">
            <meta name="dc.creator" content="Bose, Prithviraj">
            <meta name="dc.creator" content="Gandhi, Varsha">
            <meta name="dc.date" content="2017/10/31">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.11618.1">
            <meta name="dc.source" content="F1000Research 2017 6:1924">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="CLL ">
            <meta name="prism.keyword" content=" BCR pathway ">
            <meta name="prism.keyword" content=" ibrutinib ">
            <meta name="prism.keyword" content=" BTK ">
            <meta name="prism.keyword" content=" Bcl-2 ">
            <meta name="prism.keyword" content=" venetoclax ">
            <meta name="prism.keyword" content=" CD20 antibody ">
            <meta name="prism.keyword" content=" PI3K">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2017/10/31">
            <meta name="prism.volume" content="6">
            <meta name="prism.number" content="1924">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.11618.1">
            <meta name="prism.url" content="https://f1000research.com/articles/6-1924">
            <meta name="citation_title" content="Recent therapeutic advances in chronic lymphocytic leukemia">
            <meta name="citation_abstract" content="The last several years have witnessed a paradigm shift in the management of patients with chronic lymphocytic leukemia (CLL). The course of this very heterogeneous disease, traditionally treated with chemotherapeutic agents usually in combination with rituximab, typically has been characterized by remissions and relapses, and survival times vary greatly, depending on intrinsic biological attributes of the leukemia. The developments of the last few years have been transformative, ushering in an era of novel, molecularly targeted therapies, made possible by extensive efforts to elucidate the biology of the disease that predated the new targeted drugs. Thus, successful therapeutic targeting of the B-cell receptor signaling pathway and of the Bcl-2 anti-apoptotic protein with small molecules has now made chemotherapy-free approaches possible, hopefully mitigating the risk of development of therapy-related myeloid neoplasms and making eventual cure of CLL with the use of optimal drug combinations a realistic goal. Most importantly, these therapies have demonstrated unprecedented efficacy in patients with deletion 17p/TP53 mutation, a subset that historically has been very difficult to treat. However, as we gain more experience with the newer agents, unique safety concerns and resistance mechanisms have emerged, as has the issue of cost, as these expensive drugs are currently administered indefinitely. Accordingly, novel laboratory-based strategies and clinical trial designs are being explored to address these issues. The availability of whole exome/genome sequencing has given us profound insights into the mutational landscape of CLL. In this article, we highlight some of the most impactful advances since this topic was last reviewed in this journal.">
            <meta name="citation_description" content="The last several years have witnessed a paradigm shift in the management of patients with chronic lymphocytic leukemia (CLL). The course of this very heterogeneous disease, traditionally treated with chemotherapeutic agents usually in combination with rituximab, typically has been characterized by remissions and relapses, and survival times vary greatly, depending on intrinsic biological attributes of the leukemia. The developments of the last few years have been transformative, ushering in an era of novel, molecularly targeted therapies, made possible by extensive efforts to elucidate the biology of the disease that predated the new targeted drugs. Thus, successful therapeutic targeting of the B-cell receptor signaling pathway and of the Bcl-2 anti-apoptotic protein with small molecules has now made chemotherapy-free approaches possible, hopefully mitigating the risk of development of therapy-related myeloid neoplasms and making eventual cure of CLL with the use of optimal drug combinations a realistic goal. Most importantly, these therapies have demonstrated unprecedented efficacy in patients with deletion 17p/TP53 mutation, a subset that historically has been very difficult to treat. However, as we gain more experience with the newer agents, unique safety concerns and resistance mechanisms have emerged, as has the issue of cost, as these expensive drugs are currently administered indefinitely. Accordingly, novel laboratory-based strategies and clinical trial designs are being explored to address these issues. The availability of whole exome/genome sequencing has given us profound insights into the mutational landscape of CLL. In this article, we highlight some of the most impactful advances since this topic was last reviewed in this journal.">
            <meta name="citation_keywords" content="CLL, BCR pathway, ibrutinib, BTK, Bcl-2, venetoclax, CD20 antibody, PI3K">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Prithviraj Bose">
            <meta name="citation_author_institution" content="Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA">
            <meta name="citation_author" content="Varsha Gandhi">
            <meta name="citation_author_institution" content="Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA">
            <meta name="citation_author_institution" content="Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA">
            <meta name="citation_publication_date" content="2017/10/31">
            <meta name="citation_volume" content="6">
            <meta name="citation_publication_number" content="1924">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.11618.1">
            <meta name="citation_firstpage" content="1924">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/6-1924/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/6-1924.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=12549 /> <input type=hidden id=articleId name=articleId value=11618 /> <input type=hidden id=xmlUrl value="/articles/6-1924/v1/xml"/> <input type=hidden id=xmlFileName value="-6-1924-v1.xml"> <input type=hidden id=article_uuid value=50d611e1-a46a-4d46-a4cf-99a544699dcb /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Recent therapeutic advances in chronic lymphocytic leukemia"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.11618.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.11618.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/6-1924"
  },
  "headline": "Recent therapeutic advances in chronic lymphocytic leukemia",
  "datePublished": "2017-10-31T16:49:23",
  "dateModified": "2017-10-31T16:49:23",
  "author": [
    {
      "@type": "Person",
      "name": "Prithviraj Bose"
    },    {
      "@type": "Person",
      "name": "Varsha Gandhi"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "The last several years have witnessed a paradigm shift in the management of patients with chronic lymphocytic leukemia (CLL). The course of this very heterogeneous disease, traditionally treated with chemotherapeutic agents usually in combination with rituximab, typically has been characterized by remissions and relapses, and survival times vary greatly, depending on intrinsic biological attributes of the leukemia. The developments of the last few years have been transformative, ushering in an era of novel, molecularly targeted therapies, made possible by extensive efforts to elucidate the biology of the disease that predated the new targeted drugs. Thus, successful therapeutic targeting of the B-cell receptor signaling pathway and of the Bcl-2 anti-apoptotic protein with small molecules has now made chemotherapy-free approaches possible, hopefully mitigating the risk of development of therapy-related myeloid neoplasms and making eventual cure of CLL with the use of optimal drug combinations a realistic goal. Most importantly, these therapies have demonstrated unprecedented efficacy in patients with deletion 17p/TP53 mutation, a subset that historically has been very difficult to treat. However, as we gain more experience with the newer agents, unique safety concerns and resistance mechanisms have emerged, as has the issue of cost, as these expensive drugs are currently administered indefinitely. Accordingly, novel laboratory-based strategies and clinical trial designs are being explored to address these issues. The availability of whole exome/genome sequencing has given us profound insights into the mutational landscape of CLL. In this article, we highlight some of the most impactful advances since this topic was last reviewed in this journal."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/6-1924",
            "name": "Recent therapeutic advances in chronic lymphocytic leukemia"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Recent therapeutic advances in chronic lymphocytic leukemia </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=12549 data-id=11618 data-downloads="" data-views="" data-scholar="10.12688/f1000research.11618.1" data-recommended="" data-doi="10.12688/f1000research.11618.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/6-1924/v1/pdf?article_uuid=50d611e1-a46a-4d46-a4cf-99a544699dcb" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-11618-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-11618-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-11618-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Bose P and Gandhi V. Recent therapeutic advances in chronic lymphocytic leukemia [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):1924 (<a class=new-orange href="https://doi.org/10.12688/f1000research.11618.1" target=_blank>https://doi.org/10.12688/f1000research.11618.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-11618-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=11618 id=track-article-signin-11618 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/11618?target=/articles/6-1924">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=12549 /> <input name=articleId type=hidden value=11618 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Recent therapeutic advances in chronic lymphocytic leukemia</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:pbose@mdanderson.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Prithviraj Bose</span></a><sup>1</sup>,&nbsp;</span><span class=""><a href="mailto:vgandhi@mdanderson.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Varsha Gandhi</span></a><a href="https://orcid.org/0000-0002-3172-9166" target=_blank id=author-orcid-1><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-1><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-3172-9166</div><sup>1,2</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:pbose@mdanderson.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Prithviraj Bose</span></a><sup>1</sup>,&nbsp;</span><span class=""><a href="mailto:vgandhi@mdanderson.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Varsha Gandhi</span></a><a href="http://orcid.org/0000-0002-3172-9166" target=_blank id=mauthor-orcid-1><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-1><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-3172-9166</div><sup>1,2</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 31 Oct 2017 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.11618.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA<br/> <sup>2</sup> Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA<br/> <p> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=27268-27168></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=27267-27169></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> The last several years have witnessed a paradigm shift in the management of patients with chronic lymphocytic leukemia (CLL). The course of this very heterogeneous disease, traditionally treated with chemotherapeutic agents usually in combination with rituximab, typically has been characterized by remissions and relapses, and survival times vary greatly, depending on intrinsic biological attributes of the leukemia. The developments of the last few years have been transformative, ushering in an era of novel, molecularly targeted therapies, made possible by extensive efforts to elucidate the biology of the disease that predated the new targeted drugs. Thus, successful therapeutic targeting of the B-cell receptor signaling pathway and of the Bcl-2 anti-apoptotic protein with small molecules has now made chemotherapy-free approaches possible, hopefully mitigating the risk of development of therapy-related myeloid neoplasms and making eventual cure of CLL with the use of optimal drug combinations a realistic goal. Most importantly, these therapies have demonstrated unprecedented efficacy in patients with deletion 17p/TP53 mutation, a subset that historically has been very difficult to treat. However, as we gain more experience with the newer agents, unique safety concerns and resistance mechanisms have emerged, as has the issue of cost, as these expensive drugs are currently administered indefinitely. Accordingly, novel laboratory-based strategies and clinical trial designs are being explored to address these issues. The availability of whole exome/genome sequencing has given us profound insights into the mutational landscape of CLL. In this article, we highlight some of the most impactful advances since this topic was last reviewed in this journal. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> CLL, BCR pathway, ibrutinib, BTK, Bcl-2, venetoclax, CD20 antibody, PI3K </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Prithviraj Bose (<a href="mailto:pbose@mdanderson.org">pbose@mdanderson.org</a>) <br> Varsha Gandhi (<a href="mailto:vgandhi@mdanderson.org">vgandhi@mdanderson.org</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding authors:</b> Prithviraj Bose, Varsha Gandhi </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> Relevant to this manuscript, Prithviraj Bose has nothing to disclose and Varsha Gandhi has received research grants from AbbVie, Acerta, Gilead, Infinity, Pharmacyclics, and Sunesis. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The authors declared that this work was funded by National Institutes of Health (grants P30 CA016672), MD Anderson's CLL Moon shot program, and a CLL-GRF Alliance grant.<br> <br/> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2017 Bose P and Gandhi V. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Bose P and Gandhi V. Recent therapeutic advances in chronic lymphocytic leukemia [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):1924 (<a href="https://doi.org/10.12688/f1000research.11618.1" target=_blank>https://doi.org/10.12688/f1000research.11618.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 31 Oct 2017, <b>6</b>(F1000 Faculty Rev):1924 (<a href="https://doi.org/10.12688/f1000research.11618.1" target=_blank>https://doi.org/10.12688/f1000research.11618.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 31 Oct 2017, <b>6</b>(F1000 Faculty Rev):1924 (<a href="https://doi.org/10.12688/f1000research.11618.1" target=_blank>https://doi.org/10.12688/f1000research.11618.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d25947e179>Introduction</h2><p class="" id=d25947e182>The pace of discovery, with respect to both biology and therapeutic targets, as well as that of drug approval, in chronic lymphocytic leukemia (CLL) has been particularly rapid in recent years, so much so that therapeutic advances made in the treatment of CLL were named the “advance of the year” in 2015 by the American Society of Clinical Oncology. This topic was last reviewed in this journal in 2014 by Stilgenbauer and colleagues<sup><a href="#ref-1">1</a></sup>. In this article, we review more recent developments, focusing on new genomic information, novel targeted therapies, and emerging targets and drugs/drug combinations as well as new information that has accumulated on agents that had just been approved or whose approval was imminent when the last review was written, namely ibrutinib and idelalisib.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d25947e192>Recent insights into the chronic lymphocytic leukemia genome and integration of mutational information into risk stratification systems</h2><p class="" id=d25947e195>A lot has been learned on the topic of somatic mutations in CLL since the initial reports in 2011 (reviewed in <a href="#ref-2">2</a>). Two recent studies employing next-generation sequencing (either whole exome or whole genome) molecularly annotated nearly 1,000 CLL samples, identifying previously unrecognized putative driver mutations (for example, in <i>ZNF292</i>, <i>ZMYM3</i>, <i>ARID1A</i>, <i>PTPN11</i>, <i>RPS15</i>, and <i>IKZF3</i>), including some in non-coding DNA (for example, the 3′ region of <i>NOTCH1</i> that leads to aberrant splicing and increased NOTCH1 activity, and an enhancer located on chromosome 9p13 that results in reduced expression of PAX5), and many subclonal mutations and documenting frequent clonal evolution, even in the absence of therapy<sup><a href="#ref-3">3</a>,<a href="#ref-4">4</a></sup>. <i>SF3B1</i> and <i>NOTCH1</i> (previously described) represented the most frequently mutated genes in these studies<sup><a href="#ref-3">3</a>,<a href="#ref-4">4</a></sup>. The functional consequences of <i>SF3B1</i> mutations, which have been associated with faster disease progression and poor overall survival (OS) in CLL<sup><a href="#ref-5">5</a></sup>, and their near mutual exclusivity with <i>NOTCH1</i> mutations<sup><a href="#ref-6">6</a></sup> are also now better understood. The former, often associated with del(11q)<sup><a href="#ref-7">7</a></sup>, lead to alternative splicing<sup><a href="#ref-8">8</a>,<a href="#ref-9">9</a></sup>, impairment of the DNA damage response network<sup><a href="#ref-10">10</a></sup>, and dysregulation of NOTCH signaling and telomere biology<sup><a href="#ref-11">11</a></sup>. In the German CLL8 trial that compared fludarabine, cyclophosphamide, and rituximab (FCR) with fludarabine and cyclophosphamide (FC) and showed a survival advantage for the chemoimmunotherapy (CIT) combination<sup><a href="#ref-12">12</a></sup>, <i>NOTCH1</i> mutations were associated with a lower rate of response to rituximab and the lack of a survival benefit from the addition of rituximab<sup><a href="#ref-6">6</a></sup>. <i>NOTCH1</i> mutations, which are most frequently present in CLL patients with trisomy 12<sup><a href="#ref-13">13</a>,<a href="#ref-14">14</a></sup>, have subsequently been shown to lead to epigenetic dysregulation, resulting in lower CD20 expression<sup><a href="#ref-15">15</a></sup>. Del(13q), del(11q), trisomy 12, and mutations in the gene encoding MYD88, an adaptor protein in the Toll-like receptor pathway, appear to represent early genomic lesions with potential roles in CLL initiation, whereas mutations in <i>SF3B1</i>, the second allele of <i>ATM</i> and <i>TP53</i> are likely to be later genetic events<sup><a href="#ref-4">4</a>,<a href="#ref-16">16</a></sup>.</p><p class="" id=d25947e321><i>TP53</i> mutations correlate strongly with del(17p)<sup><a href="#ref-6">6</a></sup>, just as <i>ATM</i> mutations do with del(11q)<sup><a href="#ref-17">17</a></sup>. Though relatively infrequent in treatment-naïve CLL, <i>TP53</i> mutations and deletions are significantly enriched for after CIT<sup><a href="#ref-18">18</a></sup>. <i>TP53</i> mutations are independently associated with worse progression-free survival (PFS) and OS in the setting of first-line CIT<sup><a href="#ref-6">6</a></sup> and have been incorporated into the recently published CLL-International Prognostic Index (CLL-IPI)<sup><a href="#ref-19">19</a></sup>. This five-factor prognostic scoring system takes into account <i>TP53</i> status (no abnormalities versus del(17p) or <i>TP53</i> mutation or both), the mutational status of the immunoglobulin heavy chain variable region (<i>IGHV</i>), age, clinical stage, and serum beta-2-microglobulin and discriminates between four risk groups with 5-year survival rates ranging from 23.3% to 93.2%<sup><a href="#ref-19">19</a></sup>. A simple and user-friendly “biomarkers-only” prognostic model using only <i>IGHV</i> mutational status and cytogenetics by interphase fluorescence <i>in situ</i> hybridization was recently reported to perform as well as the CLL-IPI: in 524 unselected subjects with CLL, 10-year OS rates were 82% in the low-risk group, 52% in the intermediate-risk group, and 27% in the high-risk group; the model was validated in two independent cohorts, one of which was composed only of patients with Binet stage A CLL<sup><a href="#ref-20">20</a></sup>. Efforts have also been made to integrate mutational and cytogenetic information into a genetic prognostic model for patients with CLL. This model, which remained valid at any time from diagnosis, delineated four risk groups with very different 10-year survival probabilities (29%–69.3%): high risk, comprising patients with <i>TP53</i> or <i>BIRC3</i> abnormalities or both; intermediate risk, characterized by <i>NOTCH1</i> or <i>SF3B1</i> mutations or del(11q22-23) or a combination of these; low risk, consisting of patients with trisomy 12 or normal cytogenetics; and very low risk, patients with isolated del(13q14)<sup><a href="#ref-21">21</a></sup>. Among patients with early-stage disease, high CLL-cell birth rates are associated with shorter treatment-free survival<sup><a href="#ref-22">22</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d25947e404>Recent advances in targeting cell surface proteins</h2><p class="" id=d25947e407>The remarkable clinical benefits of the addition of rituximab (anti-CD20 monoclonal antibody) to chemotherapy<sup><a href="#ref-12">12</a>,<a href="#ref-23">23</a></sup> generated tremendous interest in this class of agents. Originally approved for the treatment of CLL refractory to both fludarabine and alemtuzumab, ofatumumab (Arzerra<sup>®</sup>), a fully human anti-CD20 monoclonal antibody that binds to a different epitope than rituximab, has recently been approved, along with chlorambucil, for the first-line treatment of CLL in patients deemed unfit for fludarabine-based therapy, as monotherapy for the extended treatment (“maintenance”) of patients with recurrent or progressive CLL who have received at least two lines of therapy and achieved a complete response (CR) or partial response (PR) to their most recent therapy, and in combination with FC for the treatment of patients with relapsed CLL, on the basis of the COMPLEMENT-1<sup><a href="#ref-24">24</a></sup>, PROLONG<sup><a href="#ref-25">25</a></sup>, and COMPLEMENT-2<sup><a href="#ref-26">26</a></sup> trials, respectively. However, because this agent has never been shown to be superior to rituximab in a head-to-head comparison, although such data exist for the type II glycoengineered anti-CD20 monoclonal antibody obinutuzumab (Gazyva™)<sup><a href="#ref-27">27</a></sup>, and because of the advent of the new small-molecule targeted therapies, enthusiasm for the use of ofatumumab in CLL has waned considerably. Like obinutuzumab, ublituximab (formerly TG-1101) is an anti-CD20 monoclonal antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC); the lower fucose content of its Fc domain improves its binding to FcγRIIIA<sup><a href="#ref-28">28</a>,<a href="#ref-29">29</a></sup>. In a phase 1/2 trial in patients with rituximab-relapsed or -refractory B-cell non-Hodgkin’s lymphoma (NHL) (n = 27) or CLL (n = 8), the most common adverse events (AEs) were infusion-related reactions (40%), fatigue (37%), pyrexia (29%), diarrhea (26%), neutropenia (14%), and anemia (11%)<sup><a href="#ref-30">30</a></sup>. In a phase 2 study in relapsed or refractory (R/R) CLL (n = 45) in which patients received six cycles of ublituximab in conjunction with ibrutinib, the overall response rate (ORR) was 88% at 6 months<sup><a href="#ref-31">31</a></sup>. Among 20 patients with del(17p), del(11q), or <i>TP53</i> mutation, the ORR was 95%, and three of these patients attained minimal residual disease (MRD) negativity. This combination is now being compared with ibrutinib alone in the GENUINE phase 3 study (NCT02301156) in patients with R/R CLL bearing the above genetically high-risk features. At a median follow-up of 12 months, the best ORR by independent central review was 80% for ublituximab plus ibrutinib compared with 47% for ibrutinib alone<sup><a href="#ref-32">32</a></sup>.</p><p class="" id=d25947e459>Otlertuzumab is a humanized, anti-CD37 monospecific protein therapeutic that has been studied in a phase 1 trial in 83 (mostly previously treated) patients with CLL<sup><a href="#ref-33">33</a></sup>. Twelve (20%) of sixty-one evaluable patients responded; all responses were partial and were more common in less heavily pretreated patients. This agent, in combination with bendamustine, has been compared with bendamustine alone in a small (n = 65) randomized phase 2 study in relapsed CLL<sup><a href="#ref-34">34</a></sup>. ORRs were 69% in the combination arm and 39% for bendamustine alone (<i>P</i> = 0.025), which also translated into a PFS benefit (median of 15.9 versus 10.2 months, <i>P</i> = 0.0192) for the combination. An ongoing phase 1b trial (NCT01644253) with many cohorts is studying this agent in combination with rituximab, obinutuzumab, ibrutinib, and idelalisib plus rituximab.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d25947e479>Targeting Bruton’s tyrosine kinase: ibrutinib and beyond</h2><p class="" id=d25947e482>The prototypical irreversible Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib is currently approved for all patients with CLL on the basis of the results of the RESONATE<sup><a href="#ref-35">35</a></sup>, RESONATE-2<sup><a href="#ref-36">36</a></sup>, and RESONATE-17<sup><a href="#ref-37">37</a></sup> trials. RESONATE compared ibrutinib with ofatumumab in 391 patients with R/R CLL or small lymphocytic lymphoma (SLL) and showed large improvements in ORRs and both PFS and OS<sup><a href="#ref-35">35</a></sup>, as did RESONATE-2, which compared ibrutinib with chlorambucil in 269 treatment-naïve, older (at least 65 years of age) patients with CLL or SLL<sup><a href="#ref-36">36</a></sup>. RESONATE-17 was a single-arm study of ibrutinib in 144 patients with R/R CLL or SLL and del(17p)<sup><a href="#ref-37">37</a></sup>. The ORR by independent review at the prespecified primary analysis after a median follow-up of 11.5 months was 64% (83% by investigator assessment)<sup><a href="#ref-37">37</a></sup>. After a median follow-up of 27.6 months (n = 120), the investigator-assessed ORR was 83%, 24-month PFS was 63%, and 24-month OS was 75%<sup><a href="#ref-37">37</a></sup>. Of note, complex karyotype may be a stronger predictor of inferior outcomes than del(17p) among patients with R/R CLL in the setting of ibrutinib therapy<sup><a href="#ref-38">38</a></sup>; however, not all studies have arrived at similar conclusions<sup><a href="#ref-39">39</a></sup>. Overall, responses to ibrutinib are durable and improve over time, while toxicities such as treatment-emergent grade 3/4 cytopenias, fatigue, and infections diminish<sup><a href="#ref-40">40</a></sup>. Disease progression is uncommon up to three years (median) of follow-up and mainly occurs in patients with relapsed disease harboring del(17p) or del(11q)<sup><a href="#ref-40">40</a></sup>.</p><p class="" id=d25947e535>While ibrutinib’s mobilizing effects on CLL cells resident in protective nodal microenvironmental niches and interference with their homing to the same are well known<sup><a href="#ref-41">41</a></sup>, an elegant study using deuterated water labeling has shown that the drug also has profound and immediate anti-proliferative and apoptosis-inducing actions on CLL cells<sup><a href="#ref-42">42</a></sup>. Ibrutinib is more efficient at clearing lymph node than blood or marrow disease, and recent work has demonstrated that the highest rate of CLL cell proliferation occurs in the lymph nodes<sup><a href="#ref-43">43</a></sup>. However, the “redistribution lymphocytosis” caused by ibrutinib, which has led to the introduction of the CLL response category “partial response with lymphocytosis (PR<sub>L</sub>)”<sup><a href="#ref-44">44</a></sup>, does not have any adverse long-term consequences even if prolonged, and these cells eventually die from the lack of microenvironmental pro-survival signals<sup><a href="#ref-45">45</a></sup>.</p><div class=section><a name=d25947e562 class=n-a></a><h3 class=section-title>Ibrutinib resistance and therapeutic options</h3><p class="" id=d25947e567>Resistance to ibrutinib has been attributed to acquired mutations in BTK that only allow the kinase to be reversibly bound by ibrutinib, as well as downstream mutations in phospholipase C gamma 2 (PLCγ2) that reactivate B-cell receptor (BCR) signaling despite inhibition of BTK function by ibrutinib<sup><a href="#ref-46">46</a>–<a href="#ref-48">48</a></sup>. More recent work has identified clonal evolution, particularly the emergence of del(8p) clones harboring additional driver mutations (in <i>EP300</i>, <i>MLL2</i>, and <i>EIF2A</i>), as an additional mechanism of development of resistance to ibrutinib<sup><a href="#ref-49">49</a></sup>. Outcomes after ibrutinib discontinuation have been reported to be poor<sup><a href="#ref-50">50</a>,<a href="#ref-51">51</a></sup>, particularly for patients discontinuing because of progression and especially Richter’s transformation (RT) of their CLL, but appear to be improving with the availability of newer and effective salvage options<sup><a href="#ref-52">52</a></sup>. RTs usually occur early, whereas CLL progressions generally tend to be later events<sup><a href="#ref-51">51</a></sup>. Clinical data are available supporting the efficacy of commercially available drugs such as idelalisib and venetoclax in the setting of ibrutinib resistance or intolerance (discussed below)<sup><a href="#ref-53">53</a>,<a href="#ref-54">54</a></sup> as well as investigational agents such as duvelisib (formerly IPI-145, discussed below)<sup><a href="#ref-55">55</a></sup> and entospletinib (formerly GS-9973, a spleen tyrosine kinase inhibitor)<sup><a href="#ref-56">56</a></sup>.</p><p class="" id=d25947e621>Additionally, protein kinase C beta inhibitors<sup><a href="#ref-57">57</a></sup>, heat shock protein 90 inhibitors<sup><a href="#ref-58">58</a></sup>, and selective inhibitors of nuclear export<sup><a href="#ref-59">59</a></sup> hold promise in preclinical studies to overcome ibrutinib resistance in CLL. Finally, a number of reversible BTK inhibitors that bind outside of the C481 residue targeted by ibrutinib and therefore are able to effectively inhibit the resistant C481S mutant are in development<sup><a href="#ref-60">60</a>–<a href="#ref-62">62</a></sup>.</p></div><div class=section><a name=d25947e644 class=n-a></a><h3 class=section-title>Other Bruton’s tyrosine kinase inhibitors</h3><p class="" id=d25947e649>Ibrutinib inhibits a number of kinases besides BTK, its primary therapeutic target in CLL<sup><a href="#ref-63">63</a></sup>, including some at subnanomolar concentrations<sup><a href="#ref-64">64</a></sup>. Some of these off-target effects of ibrutinib may be responsible for some of its unique toxicities (for example, atrial fibrillation<sup><a href="#ref-65">65</a></sup> and bleeding<sup><a href="#ref-66">66</a>–<a href="#ref-68">68</a></sup>). Thus, there is considerable interest in developing more selective inhibitors of BTK. Among these, acalabrutinib (formerly ACP-196) is farthest along in clinical development (phase 3). Consistent with the concept that acalabrutinib is a more selective BTK inhibitor, preclinical studies have demonstrated that ibrutinib and acalabrutinib have similar biological activity in primary CLL cells but appear to have differences in their impact on normal T cells<sup><a href="#ref-69">69</a></sup>. In a phase 1–2 study in 61 patients with relapsed CLL and a median of three prior therapies, acalabrutinib produced an ORR of 95% (85% PR and 10% PR<sub>L</sub>); all patients with del(17p) responded<sup><a href="#ref-70">70</a></sup>. In a phase 1 trial of another selective BTK inhibitor, ONO/GS-4059, in 90 patients with R/R B-cell malignancies, 24 (96%) of 25 evaluable patients with CLL responded, and the median duration of response was 80 weeks<sup><a href="#ref-71">71</a></sup>. Yet another such agent is BGB-3111<sup><a href="#ref-72">72</a></sup>. The ORR to this agent among 29 evaluable patients with R/R CLL/SLL was 90% (79% PR and 10% PR<sub>L</sub>)<sup><a href="#ref-73">73</a></sup>. With the short follow-up reported thus far, all three agents have been very well tolerated; however, there have been cases of major bleeding and atrial fibrillation reported with ONO/GS-4059 and BGB-3111<sup><a href="#ref-71">71</a>,<a href="#ref-73">73</a></sup>.</p></div><div class=section><a name=d25947e708 class=n-a></a><h3 class=section-title>Ibrutinib dose and biological activity</h3><p class="" id=d25947e713>Another approach to minimize the off-target toxicities of ibrutinib while preserving efficacy may be the exploration of lower doses<sup><a href="#ref-74">74</a></sup>. This is based on the observations that ibrutinib doses of at least 2.5 mg/kg per day were sufficient to achieve at least 95% BTK occupancy in the phase 1 trial in patients with R/R B-cell malignancies<sup><a href="#ref-75">75</a></sup> and that BTK levels decline over time in CLL cells from ibrutinib-treated patients<sup><a href="#ref-76">76</a>,<a href="#ref-77">77</a></sup>. Since ibrutinib is an irreversible inhibitor of BTK and binds to BTK in a 1:1 stoichiometric ratio, this would imply the need for lower doses of ibrutinib over time as BTK levels decline. Therefore, continued dosing at 420 mg/day could lead to greater off-target binding and toxicity<sup><a href="#ref-74">74</a></sup>. Our group is currently studying the pharmacodynamic correlates, including BTK occupancy, of progressively lower dosing of ibrutinib in patients with CLL in the context of a pilot study (NCT02801578). Importantly, a retrospective multi-institutional “real world” study published recently showed that reduced dose ibrutinib—defined as sustained (for at least 2 months) dosing at less than 420 mg/day, either at treatment initiation or within 3 months from starting ibrutinib—did not compromise outcomes (that is, ORR or PFS)<sup><a href="#ref-78">78</a></sup>. Toxicity or physician preference drove the decision to reduce the dose of ibrutinib in the vast majority of cases. In contrast, missing<i></i> at least 8 consecutive days of ibrutinib has been correlated with shorter median PFS<sup><a href="#ref-79">79</a></sup>.</p></div><div class=section><a name=d25947e747 class=n-a></a><h3 class=section-title>Combination strategies involving ibrutinib</h3><p class="" id=d25947e752>Ibrutinib has been combined with anti-CD20 monoclonal antibodies in non-comparative clinical trials<sup><a href="#ref-80">80</a>,<a href="#ref-81">81</a></sup>, and although early fears of antagonism of rituximab-mediated ADCC by ibrutinib based on preclinical studies<sup><a href="#ref-82">82</a></sup> have been laid to rest, the incremental benefit of this approach (versus ibrutinib alone) is not clear. Similarly, the HELIOS study in 578 patients with R/R non-del(17p) CLL or SLL showed improved PFS with the addition of ibrutinib to bendamustine and rituximab (BR), but this regimen does not appear to offer meaningful advantages over ibrutinib monotherapy, except when a rapid response is clinically desirable<sup><a href="#ref-83">83</a></sup>. One US cooperative group study is investigating BR, ibrutinib alone, or ibrutinib plus rituximab in previously untreated patients at least 65 years of age (NCT01886872), while another is comparing frontline FCR with ibrutinib plus rituximab in patients 18 to 70 years of age (NCT02048813). Accrual to both of these studies is complete and results are awaited.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d25947e774>Targeting phosphatidylinositol-3-kinase: idelalisib and newer inhibitors</h2><div class=section><a name=d25947e777 class=n-a></a><h3 class=section-title>Idelalisib</h3><p class="" id=d25947e782>The first-in-class phosphatidylinositol-3-kinase (PI3K) delta isoform-specific inhibitor idelalisib (Zydelig<sup>®</sup>) was approved in conjunction with rituximab by the US Food and Drug Administration (FDA) in 2014 for patients with relapsed CLL for whom rituximab alone would be considered appropriate therapy (because of co-morbidities) on the basis of the results of a pivotal phase 3 study in which the combination significantly improved both PFS and OS over rituximab plus placebo, so much so that the trial was stopped early<sup><a href="#ref-84">84</a></sup>. Like ibrutinib, idelalisib blocks signaling through the BCR pathway and is efficacious in patients harboring del(17p) or <i>TP53</i> aberrations. We have recently shown that in mantle cell lymphoma cell lines and patient-derived samples, idelalisib inhibits protein synthesis, which correlates with reductions in AKT (the immediate downstream effector of PI3K) and mitogen-activated protein kinase kinase (MEK) phosphorylation<sup><a href="#ref-85">85</a></sup>. Idelalisib synergizes with bendamustine in primary CLL cells, increasing DNA damage and suppressing transcription of the anti-apoptotic protein myeloid cell leukemia 1 (MCL-1)<sup><a href="#ref-86">86</a></sup>. Indeed, in a recently reported phase 3 trial (n = 416), the combination of idelalisib with BR markedly enhanced PFS in patients with R/R CLL (median of 20.8 versus 11.1 months for BR plus placebo after a median follow-up of 14 months)<sup><a href="#ref-87">87</a></sup>. Idelalisib plus ofatumumab has also been compared with ofatumumab alone in 261 patients with R/R CLL (median number of prior therapies = 3) in a randomized phase 3 trial<sup><a href="#ref-88">88</a></sup>. The primary analysis of this trial showed a doubling of median PFS (16.3 versus 8 months) in the combination arm.</p><p class="" id=d25947e812>The use of idelalisib in patients with CLL has been constrained by toxicity concerns, particularly given the superior safety profile of ibrutinib. The US prescribing information for idelalisib contains a black-box warning for fatal or serious hepatotoxicity or both (11%–18%), diarrhea/colitis (14%–19%), pneumonitis (4%), infections (21%–36%), and intestinal perforation, and a high degree of vigilance for these AEs is essential in patients receiving idelalisib. The incidence of hepatotoxicity, believed to be immune-mediated, has been reported to be particularly high in the setting of frontline idelalisib monotherapy; 19 (79%) of 24 subjects experienced some degree of transaminitis and 13 (54%) had at least grade 3 transaminitis in a recent study<sup><a href="#ref-89">89</a></sup>. The median time to development of transaminitis was 28 days, and younger age and mutated <i>IGHV</i> status predicted for this complication. Very recently, it was reported that PI3K delta blockade by either idelalisib or duvelisib (discussed below), through upregulation of the B cell–specific enzyme activation-induced cytidine deaminase, induces genomic instability in normal and neoplastic B cells, which could lead to lymphomagenesis given the potential for patients to be on these drugs for prolonged periods<sup><a href="#ref-90">90</a></sup>.</p></div><div class=section><a name=d25947e827 class=n-a></a><h3 class=section-title>Other PI3K inhibitors</h3><p class="" id=d25947e832>TGR-1202 is a novel PI3K delta inhibitor with an improved safety profile, particularly with regard to hepatotoxicity and colitis. In a phase 1 study in patients with R/R CLL or NHL, 10 (63%) of 16 evaluable patients with CLL achieved a PR. This agent has been combined with ublituximab: of 10 R/R CLL patients who received the combination, all were progression-free at a median of 8 months when these data were last presented. A pivotal phase 3 trial (UNITY-CLL) comparing ublituximab and TGR-1202 with chlorambucil and obinutuzumab is under way (NCT02612311), as are a number of other studies combining TGR-1202 or TGR-1202 plus ublituximab with ibrutinib, bendamustine, or pembrolizumab.</p><p class="" id=d25947e835>Duvelisib (reviewed in <a href="#ref-91">91</a>) is a small-molecule inhibitor of both the delta and gamma isoforms of PI3K that potently and selectively inhibits the proliferation of primary CLL cells, induces apoptosis, and interferes with the homing capabilities of CLL cells through blockade of BCR signaling<sup><a href="#ref-92">92</a></sup>. Preclinically, duvelisib impairs the viability of T cells and natural killer cells and decreases the production by activated T cells of inflammatory and anti-apoptotic cytokines<sup><a href="#ref-93">93</a></sup>. ORRs to single-agent duvelisib have ranged from 55% in heavily pretreated patients with R/R CLL to 82% in previously untreated patients; as with ibrutinib and idelalisib, the vast majority of responses have been partial<sup><a href="#ref-94">94</a>,<a href="#ref-95">95</a></sup>. Duvelisib has been studied in combination with bendamustine, rituximab, and BR in patients with R/R CLL or indolent NHL with good tolerability<sup><a href="#ref-96">96</a></sup>. In treatment-naïve patients, the addition of duvelisib to FCR appears to substantially increase the rate of MRD negativity<sup><a href="#ref-97">97</a></sup>, a strong surrogate for long-term outcome in CLL<sup><a href="#ref-98">98</a></sup>. Results of the completed phase 3 DUO study (NCT02004522) comparing duvelisib with ofatumumab in 319 patients with R/R CLL or SLL are expected soon; the trial has met its primary endpoint of significantly improved PFS in the duvelisib arm (13.3 versus 9.9 months), according to topline results released recently by the company.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d25947e874>Targeting B-cell lymphoma 2 with venetoclax</h2><p class="" id=d25947e877>CLL cells are exquisitely dependent on the B-cell lymphoma 2 (BCL-2) anti-apoptotic protein for survival<sup><a href="#ref-99">99</a></sup>, and the “BH3-mimetic” navitoclax, an antagonist of both BCL-2 and BCL-xL, showed promising activity in patients with R/R CLL<sup><a href="#ref-100">100</a></sup>, but the development of this agent was hampered by the occurrence of dose-limiting thrombocytopenia in all clinical trials, an on-target consequence of the drug’s action on platelets and megakaryocytes, which rely on BCL-xL for survival<sup><a href="#ref-101">101</a></sup>. These observations led to the development of venetoclax (Venclexta™, formerly ABT-199), a highly BCL-2–selective antagonist that spares platelets<sup><a href="#ref-102">102</a></sup>, by reverse engineering of navitoclax.</p><p class="" id=d25947e896>In a phase 1 trial with dose escalation and expansion phases, 116 patients with R/R CLL or SLL (but none previously treated with BCR inhibitors) received venetoclax<sup><a href="#ref-103">103</a></sup>. The ORR was 79%, including CRs in 20% of patients, a quarter of which were MRD-negative. Clinical tumor lysis syndrome (TLS), fatal in one case, occurred in three of 56 patients in the dose escalation phase, but did not recur in the dose expansion phase (n = 60), after a careful dose ramp-up to a maximum of 400 mg daily was instituted. Mild diarrhea (52%), upper respiratory infection (48%), nausea (47%), and grade 3/4 neutropenia (41%) were frequent. Venetoclax was approved in 2016 by the FDA for patients with CLL with del(17p) based on an ORR of 79.4% in a separate study (n = 107) carried out exclusively in patients with R/R del(17p) CLL<sup><a href="#ref-104">104</a></sup>. The CR rate, with or without complete count recovery, in this study was only 8%, and only 5% of the patients had received prior BCR inhibitors. Grade 3/4 neutropenia was very common (40%), and grade 3/4 infections, anemia, and thrombocytopenia occurred in 20%, 18%, and 15% of patients, respectively. According to the current label, the dose of venetoclax should be ramped up over a 4- to 5-week period from 20 to 400 mg daily to minimize the risk of TLS. Venetoclax was combined with rituximab in a phase 1 trial in 49 patients with R/R CLL or SLL, and the recommended phase 2 dose (RP2D) was found to be 400 mg/day in this setting as well<sup><a href="#ref-105">105</a></sup>. Clinical TLS occurred in two patients who started the dose ramp-up at 50 mg/day, and resulted in one death. The ORR was 86% and MRD negativity was attained in 57%. Twenty-five patients (51%) achieved CR and 20 of them (80%) were MRD-negative. Grade 1/2 upper respiratory infection, diarrhea, and nausea were very frequent, affecting 57%, 55%, and 51% of patients, respectively. Grade 3/4 neutropenia affected 53% of patients, and febrile neutropenia 12%; 14% and 16% of patients, respectively, had grade 3/4 anemia and thrombocytopenia.</p><p class="" id=d25947e911>An important question not addressed by the above studies concerns the efficacy of venetoclax in patients failing BCR inhibitors. This is the subject of an ongoing study, preliminary results of which have been presented<sup><a href="#ref-53">53</a></sup>. The study enrolled only patients who had relapsed or were refractory to ibrutinib (n = 43) or idelalisib (n = 21). The ORRs to venetoclax monotherapy were 70% in the prior ibrutinib group and 48% in the prior idelalisib group. Only one CR (with incomplete count recovery) was documented by independent review—in the prior ibrutinib group.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d25947e921>Combination strategies and the road to a cure in chronic lymphocytic leukemia</h2><p class="" id=d25947e924>Long-term (more than 10 years) relapse-free remissions are already achievable with FCR in the subset of patients with favorable genomic prognostic factors (that is, mutated <i>IGHV</i>, del(13q), normal cytogenetics, or trisomy 12)<sup><a href="#ref-106">106</a></sup>. Ongoing clinical trials are attempting to further improve outcomes by adding ibrutinib to frontline FCR, followed by ibrutinib maintenance in younger, fit patients<sup><a href="#ref-107">107</a></sup>, or adding ibrutinib and replacing rituximab with the more potent obinutuzumab, while reducing the exposure to cytotoxic chemotherapy (to mitigate the real risk of therapy-related myeloid neoplasms)<sup><a href="#ref-108">108</a></sup>, as well as limiting the duration of ibrutinib maintenance using an MRD-driven approach in previously untreated patients with mutated <i>IGHV</i> and without del(17p)<sup><a href="#ref-109">109</a></sup>. Achievement of MRD negativity has become widely established as a necessary first step to an eventual cure of CLL (reviewed in <a href="#ref-110">110</a>).</p><p class="" id=d25947e953>Preclinical studies from our group<sup><a href="#ref-111">111</a></sup> and others<sup><a href="#ref-112">112</a></sup> have demonstrated synergism between ibrutinib and venetoclax in CLL. The clinical efficacy profiles of these two oral agents also complement each other well, as ibrutinib is particularly effective at clearing nodal disease and less so at clearing marrow disease, whereas venetoclax has the opposite profile and also does not cause the redistribution lymphocytosis typical of BCR inhibitors. Furthermore, CR rates with ibrutinib monotherapy, at least in the R/R setting, are very low<sup><a href="#ref-35">35</a>,<a href="#ref-113">113</a></sup> and clearly better with venetoclax, which is additionally capable of inducing MRD negativity on its own<sup><a href="#ref-103">103</a></sup>. These observations make this a particularly attractive combination, which is being studied in several ongoing clinical trials in both the frontline and R/R settings (NCT02756897, NCT03045328, and NCT02910583). Other trials are studying the triple combination of ibrutinib, venetoclax, and obinutuzumab (NCT02758665 and NCT02427451). Early results demonstrate tolerability of the triple combination, and the RP2D of venetoclax is the same as the approved monotherapy dose (that is, 400 mg/day)<sup><a href="#ref-114">114</a></sup>. Aside from toxicity concerns, the enormous economic burden of indefinite therapy of CLL with the new oral targeted agents<sup><a href="#ref-115">115</a></sup> makes achievement of a deep response with the use of an optimal combination regimen for a finite duration with, hopefully, a durable treatment-free remission an important goal.</p><p class="" id=d25947e984>Duvelisib has also been shown to synergize with venetoclax in induction of apoptosis of CLL cells<sup><a href="#ref-116">116</a></sup>. However, there are no ongoing clinical studies of PI3K delta inhibitors in combination with venetoclax; one involving duvelisib was withdrawn. This could reflect the substantial toxicity concerns with idelalisib discussed above, as well as the recent findings of induction of genomic instability in B cells by both idelalisib and duvelisib<sup><a href="#ref-90">90</a></sup>. If indeed TGR-1202 turns out to have a much improved safety profile in the clinic, it is possible that the combination of this agent with venetoclax will be pursued in trials.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d25947e998>Emerging drug targets</h2><p class="" id=d25947e1001>Single-agent immune checkpoint blockade with pembrolizumab (Keytruda<sup>®</sup>), a monoclonal antibody directed against programmed death 1 (PD-1), was recently shown to have substantial clinical activity in patients with RT, a difficult-to-treat, poor-prognosis entity, but not in CLL<sup><a href="#ref-117">117</a></sup>. As noted above, this agent is also being studied in combination with ublituximab plus TGR-1202 in patients with R/R CLL or RT (NCT02535286). Additionally, it is being evaluated in combination with ibrutinib or idelalisib in patients with R/R CLL (NCT02332980). The anti–PD-1 monoclonal antibody nivolumab (Opdivo<sup>®</sup>) is also being evaluated in combination with ibrutinib in both patients with RT and R/R or high-risk CLL (NCT02420912). Studies in mouse models of lymphoma support the combination of ibrutinib with immune checkpoint blockade<sup><a href="#ref-118">118</a></sup>. This is based, in part, on the inhibition by ibrutinib of interleukin-2-inducible kinase (ITK) in T cells, which skews T-cell immune responses away from Th2 and toward a Th1 phenotype<sup><a href="#ref-119">119</a></sup>.</p><p class="" id=d25947e1022>Resistance to venetoclax is largely driven by MCL-1 (reviewed in <a href="#ref-120">120</a>); for years, this anti-apoptotic protein has eluded therapeutic targeting. However, a number of clinical candidate compounds capable of directly antagonizing the function of MCL-1 are now on the horizon<sup><a href="#ref-121">121</a>–<a href="#ref-123">123</a></sup> and hopefully will be available in the future for combination with venetoclax. Furthermore, therapy with BCR axis inhibitors such as ibrutinib<sup><a href="#ref-111">111</a></sup>, acalabrutinib<sup><a href="#ref-69">69</a></sup>, idelalisib<sup><a href="#ref-124">124</a></sup>, and duvelisib<sup><a href="#ref-116">116</a></sup> results in a decline in MCL-1 protein levels in CLL cells, providing a mechanism-based rationale to combine them with venetoclax. Another strategy involves downregulating this short-lived anti-apoptotic protein through transcriptional repression, achievable by inhibition of cyclin-dependent kinase 9 (CDK9)<sup><a href="#ref-125">125</a></sup>. While “pan”-CDK inhibitors have displayed clear evidence of activity in CLL<sup><a href="#ref-126">126</a>,<a href="#ref-127">127</a></sup>, current efforts in this area are focusing on developing agents that are selective for CDK9. CYC065, for example, is highly selective for CDK2 and CDK9.</p><p class="" id=d25947e1063>A relatively new therapeutic target in CLL is colony-stimulating factor 1R (CSF1R), expressed on tumor-associated macrophages (TAMs), and macrophage killing by CSF1R blockade induces CLL cell death, primarily through the tumor necrosis factor pathway<sup><a href="#ref-128">128</a></sup>. TAMs provide support to CLL cells via a PI3K-AKT-mammalian target of rapamycin (mTOR)-dependent translational upregulation of MCL-1<sup><a href="#ref-129">129</a></sup>. Both small-molecule kinase inhibitors (for example, pexidartinib<sup><a href="#ref-130">130</a></sup> and BLZ945<sup><a href="#ref-131">131</a></sup>) and monoclonal antibodies targeting CSF1R are in development for various tumor types.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d25947e1085>Conclusions</h2><p class="" id=d25947e1088>The past few years have seen enormous advancements in our understanding of CLL biology and drug discovery and clinical development. The advent of the BCR inhibitors and venetoclax has fundamentally changed the paradigm of CLL management and brought unprecedented benefits to patients, particularly those with historically poor outcomes with CIT (for example, those with del(17p) or <i>TP53</i> abnormalities). The challenges facing the field in the coming years will be how to optimally combine and sequence these and newer agents so as to achieve high rates of MRD eradication, hopefully enabling treatment discontinuation and translating to long-term relapse-free survival. Identification of mechanisms of resistance to the novel targeted agents and their abrogation, along with effective treatment and prevention of RT, will likely become a major focus of CLL research in the years to come. New drugs targeted against CD37, MCL-1, CDK9, CSF1R, and so on hold promise for an even more robust therapeutic armamentarium in the near future.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d25947e1 class=n-a></a><h2 class=main-title id=d26376>Competing interests</h2><p class=metadata-entry><a name=d25947e111 class=n-a></a><p id=d25947e113> Relevant to this manuscript, Prithviraj Bose has nothing to disclose and Varsha Gandhi has received research grants from AbbVie, Acerta, Gilead, Infinity, Pharmacyclics, and Sunesis.</p></p></div><div class=back-section><a name=d25947e1 class=n-a></a><h2 class=main-title id=d26378>Grant information</h2><p>The authors declared that this work was funded by National Institutes of Health (grants P30 CA016672), MD Anderson’s CLL Moon shot program, and a CLL-GRF Alliance grant.</p></div><div class=back-section><a name=d25947e1098 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d26832>References</h2><div class="section ref-list"><a name=d25947e1098 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d25947e1105 class=n-a></a>Tausch E, Mertens D, Stilgenbauer S: Advances in treating chronic lymphocytic leukemia. <i>F1000Prime Rep.</i> 2014; <b>6</b>: 65. <a target=xrefwindow id=d25947e1113 href="http://www.ncbi.nlm.nih.gov/pubmed/25165564">PubMed Abstract </a> | <a target=xrefwindow id=d25947e1116 href="http://dx.doi.org/10.12703/P6-65">Publisher Full Text </a> | <a target=xrefwindow id=d25947e1119 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4126532">Free Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d25947e1128 class=n-a></a>Lazarian G, Guièze R, Wu CJ: Clinical Implications of Novel Genomic Discoveries in Chronic Lymphocytic Leukemia. <i>J Clin Oncol.</i> 2017; <b>35</b>(9): 984–93. <a target=xrefwindow id=d25947e1136 href="http://www.ncbi.nlm.nih.gov/pubmed/28297623">PubMed Abstract </a> | <a target=xrefwindow id=d25947e1139 href="http://dx.doi.org/10.1200/JCO.2016.71.0822">Publisher Full Text </a> | <a target=xrefwindow id=d25947e1142 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5559883">Free Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725663787"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25947e1151 class=n-a></a>Puente XS, Beà S, Valdés-Mas R, <i> et al.</i>: Non-coding recurrent mutations in chronic lymphocytic leukaemia. <i>Nature.</i> 2015; <b>526</b>(7574): 519–24. <a target=xrefwindow id=d25947e1162 href="http://www.ncbi.nlm.nih.gov/pubmed/26200345">PubMed Abstract </a> | <a target=xrefwindow id=d25947e1165 href="http://dx.doi.org/10.1038/nature14666">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725663787">F1000 Recommendation</a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725850404"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25947e1178 class=n-a></a>Landau DA, Tausch E, Taylor-Weiner AN, <i> et al.</i>: Mutations driving CLL and their evolution in progression and relapse. <i>Nature.</i> 2015; <b>526</b>(7574): 525–30. <a target=xrefwindow id=d25947e1189 href="http://www.ncbi.nlm.nih.gov/pubmed/26466571">PubMed Abstract </a> | <a target=xrefwindow id=d25947e1192 href="http://dx.doi.org/10.1038/nature15395">Publisher Full Text </a> | <a target=xrefwindow id=d25947e1196 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4815041">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725850404">F1000 Recommendation</a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d25947e1209 class=n-a></a>Quesada V, Conde L, Villamor N, <i> et al.</i>: Exome sequencing identifies recurrent mutations of the splicing factor <i>SF3B1</i> gene in chronic lymphocytic leukemia. <i>Nat Genet.</i> 2011; <b>44</b>(1): 47–52. <a target=xrefwindow id=d25947e1223 href="http://www.ncbi.nlm.nih.gov/pubmed/22158541">PubMed Abstract </a> | <a target=xrefwindow id=d25947e1227 href="http://dx.doi.org/10.1038/ng.1032">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d25947e1237 class=n-a></a>Stilgenbauer S, Schnaiter A, Paschka P, <i> et al.</i>: Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. <i>Blood.</i> 2014; <b>123</b>(21): 3247–54. <a target=xrefwindow id=d25947e1248 href="http://www.ncbi.nlm.nih.gov/pubmed/24652989">PubMed Abstract </a> | <a target=xrefwindow id=d25947e1251 href="http://dx.doi.org/10.1182/blood-2014-01-546150">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/13410996"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25947e1260 class=n-a></a>Wang L, Lawrence MS, Wan Y, <i> et al.</i>: <i>SF3B1</i> and other novel cancer genes in chronic lymphocytic leukemia. <i>N Engl J Med.</i> 2011; <b>365</b>(26): 2497–506. <a target=xrefwindow id=d25947e1274 href="http://www.ncbi.nlm.nih.gov/pubmed/22150006">PubMed Abstract </a> | <a target=xrefwindow id=d25947e1278 href="http://dx.doi.org/10.1056/NEJMoa1109016">Publisher Full Text </a> | <a target=xrefwindow id=d25947e1281 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3685413">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/13410996">F1000 Recommendation</a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d25947e1294 class=n-a></a>Darman RB, Seiler M, Agrawal AA, <i> et al.</i>: Cancer-Associated <i>SF3B1</i> Hotspot Mutations Induce Cryptic 3' Splice Site Selection through Use of a Different Branch Point. <i>Cell Rep.</i> 2015; <b>13</b>(5): 1033–45. <a target=xrefwindow id=d25947e1308 href="http://www.ncbi.nlm.nih.gov/pubmed/26565915">PubMed Abstract </a> | <a target=xrefwindow id=d25947e1312 href="http://dx.doi.org/10.1016/j.celrep.2015.09.053">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d25947e1321 class=n-a></a>DeBoever C, Ghia EM, Shepard PJ, <i> et al.</i>: Transcriptome sequencing reveals potential mechanism of cryptic 3' splice site selection in <i>SF3B1</i>-mutated cancers. <i>PLoS Comput Biol.</i> 2015; <b>11</b>(3): e1004105. <a target=xrefwindow id=d25947e1335 href="http://www.ncbi.nlm.nih.gov/pubmed/25768983">PubMed Abstract </a> | <a target=xrefwindow id=d25947e1339 href="http://dx.doi.org/10.1371/journal.pcbi.1004105">Publisher Full Text </a> | <a target=xrefwindow id=d25947e1342 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4358997">Free Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d25947e1351 class=n-a></a>Te Raa GD, Derks IA, Navrkalova V, <i> et al.</i>: The impact of <i>SF3B1</i> mutations in CLL on the DNA-damage response. <i>Leukemia.</i> 2015; <b>29</b>(5): 1133–42. <a target=xrefwindow id=d25947e1365 href="http://www.ncbi.nlm.nih.gov/pubmed/25371178">PubMed Abstract </a> | <a target=xrefwindow id=d25947e1369 href="http://dx.doi.org/10.1038/leu.2014.318">Publisher Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d25947e1378 class=n-a></a>Wang L, Brooks AN, Fan J, <i> et al.</i>: Transcriptomic Characterization of <i>SF3B1</i> Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia. <i>Cancer Cell.</i> 2016; <b>30</b>(5): 750–63. <a target=xrefwindow id=d25947e1392 href="http://www.ncbi.nlm.nih.gov/pubmed/27818134">PubMed Abstract </a> | <a target=xrefwindow id=d25947e1396 href="http://dx.doi.org/10.1016/j.ccell.2016.10.005">Publisher Full Text </a> | <a target=xrefwindow id=d25947e1399 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5127278">Free Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d25947e1409 class=n-a></a>Hallek M, Fischer K, Fingerle-Rowson G, <i> et al.</i>: Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. <i>Lancet.</i> 2010; <b>376</b>(9747): 1164–74. <a target=xrefwindow id=d25947e1420 href="http://www.ncbi.nlm.nih.gov/pubmed/20888994">PubMed Abstract </a> | <a target=xrefwindow id=d25947e1423 href="http://dx.doi.org/10.1016/S0140-6736(10)61381-5">Publisher Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d25947e1432 class=n-a></a>Balatti V, Bottoni A, Palamarchuk A, <i> et al.</i>: <i>NOTCH1</i> mutations in CLL associated with trisomy 12. <i>Blood.</i> 2012; <b>119</b>(2): 329–31. <a target=xrefwindow id=d25947e1446 href="http://www.ncbi.nlm.nih.gov/pubmed/22086416">PubMed Abstract </a> | <a target=xrefwindow id=d25947e1450 href="http://dx.doi.org/10.1182/blood-2011-10-386144">Publisher Full Text </a> | <a target=xrefwindow id=d25947e1453 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3257004">Free Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d25947e1462 class=n-a></a>Riches JC, O'Donovan CJ, Kingdon SJ, <i> et al.</i>: Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by <i>NOTCH1</i> mutations. <i>Blood.</i> 2014; <b>123</b>(26): 4101–10. <a target=xrefwindow id=d25947e1476 href="http://www.ncbi.nlm.nih.gov/pubmed/24829201">PubMed Abstract </a> | <a target=xrefwindow id=d25947e1480 href="http://dx.doi.org/10.1182/blood-2014-01-552307">Publisher Full Text </a> | <a target=xrefwindow id=d25947e1483 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4073326">Free Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d25947e1492 class=n-a></a>Pozzo F, Bittolo T, Arruga F, <i> et al.</i>: <i>NOTCH1</i> mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation. <i>Leukemia.</i> 2016; <b>30</b>(1): 182–9. <a target=xrefwindow id=d25947e1506 href="http://www.ncbi.nlm.nih.gov/pubmed/26165233">PubMed Abstract </a> | <a target=xrefwindow id=d25947e1510 href="http://dx.doi.org/10.1038/leu.2015.182">Publisher Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d25947e1519 class=n-a></a>Landau DA, Carter SL, Stojanov P, <i> et al.</i>: Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. <i>Cell.</i> 2013; <b>152</b>(4): 714–26. <a target=xrefwindow id=d25947e1530 href="http://www.ncbi.nlm.nih.gov/pubmed/23415222">PubMed Abstract </a> | <a target=xrefwindow id=d25947e1533 href="http://dx.doi.org/10.1016/j.cell.2013.01.019">Publisher Full Text </a> | <a target=xrefwindow id=d25947e1537 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3575604">Free Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d25947e1546 class=n-a></a>Austen B, Skowronska A, Baker C, <i> et al.</i>: Mutation status of the residual <i>ATM</i> allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. <i>J Clin Oncol.</i> 2007; <b>25</b>(34): 5448–57. <a target=xrefwindow id=d25947e1560 href="http://www.ncbi.nlm.nih.gov/pubmed/17968022">PubMed Abstract </a> | <a target=xrefwindow id=d25947e1564 href="http://dx.doi.org/10.1200/JCO.2007.11.2649">Publisher Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d25947e1574 class=n-a></a>Edelmann J, Tausch E, Landau DA, <i> et al.</i>: Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with <i>TP53</i> alterations: results from the CLL8 trial. <i>Leukemia.</i> 2017; <b>31</b>(3): 734–8. <a target=xrefwindow id=d25947e1588 href="http://www.ncbi.nlm.nih.gov/pubmed/27909343">PubMed Abstract </a> | <a target=xrefwindow id=d25947e1592 href="http://dx.doi.org/10.1038/leu.2016.317">Publisher Full Text </a> | <a target=xrefwindow id=d25947e1595 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5332302">Free Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d25947e1604 class=n-a></a>International CLL-IPI working group: An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. <i>Lancet Oncol.</i> 2016; <b>17</b>(6): 779–90. <a target=xrefwindow id=d25947e1612 href="http://www.ncbi.nlm.nih.gov/pubmed/27185642">PubMed Abstract </a> | <a target=xrefwindow id=d25947e1615 href="http://dx.doi.org/10.1016/S1470-2045(16)30029-8">Publisher Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727245367"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25947e1624 class=n-a></a>Delgado J, Doubek M, Baumann T, <i> et al.</i>: Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (<i>IGHV</i> mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI. <i>Am J Hematol.</i> 2017; <b>92</b>(4): 375–80. <a target=xrefwindow id=d25947e1638 href="http://www.ncbi.nlm.nih.gov/pubmed/28120419">PubMed Abstract </a> | <a target=xrefwindow id=d25947e1642 href="http://dx.doi.org/10.1002/ajh.24660">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727245367">F1000 Recommendation</a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d25947e1655 class=n-a></a>Rossi D, Rasi S, Spina V, <i> et al.</i>: Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. <i>Blood.</i> 2013; <b>121</b>(8): 1403–12. <a target=xrefwindow id=d25947e1666 href="http://www.ncbi.nlm.nih.gov/pubmed/23243274">PubMed Abstract </a> | <a target=xrefwindow id=d25947e1669 href="http://dx.doi.org/10.1182/blood-2012-09-458265">Publisher Full Text </a> | <a target=xrefwindow id=d25947e1673 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3578955">Free Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727237482"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25947e1682 class=n-a></a>Murphy EJ, Neuberg DS, Rassenti LZ, <i> et al.</i>: Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia. <i>Leukemia.</i> 2017; <b>31</b>(6): 1348–54. <a target=xrefwindow id=d25947e1693 href="http://www.ncbi.nlm.nih.gov/pubmed/28115735">PubMed Abstract </a> | <a target=xrefwindow id=d25947e1696 href="http://dx.doi.org/10.1038/leu.2017.34">Publisher Full Text </a> | <a target=xrefwindow id=d25947e1700 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5462857">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727237482">F1000 Recommendation</a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d25947e1713 class=n-a></a>Keating MJ, O'Brien S, Albitar M, <i> et al.</i>: Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. <i>J Clin Oncol.</i> 2005; <b>23</b>(18): 4079–88. <a target=xrefwindow id=d25947e1724 href="http://www.ncbi.nlm.nih.gov/pubmed/15767648">PubMed Abstract </a> | <a target=xrefwindow id=d25947e1727 href="http://dx.doi.org/10.1200/JCO.2005.12.051">Publisher Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d25947e1737 class=n-a></a>Hillmen P, Robak T, Janssens A, <i> et al.</i>: Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. <i>Lancet.</i> 2015; <b>385</b>(9980): 1873–83. <a target=xrefwindow id=d25947e1748 href="http://www.ncbi.nlm.nih.gov/pubmed/25882396">PubMed Abstract </a> | <a target=xrefwindow id=d25947e1751 href="http://dx.doi.org/10.1016/S0140-6736(15)60027-7">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d25947e1760 class=n-a></a>van Oers MH, Kuliczkowski K, Smolej L, <i> et al.</i>: Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. <i>Lancet Oncol.</i> 2015; <b>16</b>(13): 1370–9. <a target=xrefwindow id=d25947e1771 href="http://www.ncbi.nlm.nih.gov/pubmed/26377300">PubMed Abstract </a> | <a target=xrefwindow id=d25947e1774 href="http://dx.doi.org/10.1016/S1470-2045(15)00143-6">Publisher Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d25947e1783 class=n-a></a>Robak T, Warzocha K, Govind Babu K, <i> et al.</i>: Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial. <i>Leuk Lymphoma.</i> 2017; <b>58</b>(5): 1084–93. <a target=xrefwindow id=d25947e1794 href="http://www.ncbi.nlm.nih.gov/pubmed/27731748">PubMed Abstract </a> | <a target=xrefwindow id=d25947e1797 href="http://dx.doi.org/10.1080/10428194.2016.1233536">Publisher Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718232166"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25947e1806 class=n-a></a>Goede V, Fischer K, Busch R, <i> et al.</i>: Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. <i>N Engl J Med.</i> 2014; <b>370</b>(12): 1101–10. <a target=xrefwindow id=d25947e1817 href="http://www.ncbi.nlm.nih.gov/pubmed/24401022">PubMed Abstract </a> | <a target=xrefwindow id=d25947e1820 href="http://dx.doi.org/10.1056/NEJMoa1313984">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718232166">F1000 Recommendation</a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d25947e1833 class=n-a></a>de Romeuf C, Dutertre CA, Le Garff-Tavernier M, <i> et al.</i>: Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16. <i>Br J Haematol.</i> 2008; <b>140</b>(6): 635–43. <a target=xrefwindow id=d25947e1844 href="http://www.ncbi.nlm.nih.gov/pubmed/18302712">PubMed Abstract </a> | <a target=xrefwindow id=d25947e1847 href="http://dx.doi.org/10.1111/j.1365-2141.2007.06974.x">Publisher Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d25947e1856 class=n-a></a>Le Garff-Tavernier M, Herbi L, de Romeuf C, <i> et al.</i>: Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion. <i>Leukemia.</i> 2014; <b>28</b>(1): 230–3. <a target=xrefwindow id=d25947e1867 href="http://www.ncbi.nlm.nih.gov/pubmed/23958919">PubMed Abstract </a> | <a target=xrefwindow id=d25947e1870 href="http://dx.doi.org/10.1038/leu.2013.240">Publisher Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727328356"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25947e1880 class=n-a></a>Sawas A, Farber CM, Schreeder MT, <i> et al.</i>: A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab. <i>Br J Haematol.</i> 2017; <b>177</b>(2): 243–53. <a target=xrefwindow id=d25947e1891 href="http://www.ncbi.nlm.nih.gov/pubmed/28220479">PubMed Abstract </a> | <a target=xrefwindow id=d25947e1894 href="http://dx.doi.org/10.1111/bjh.14534">Publisher Full Text </a> | <a target=xrefwindow id=d25947e1898 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5412890">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727328356">F1000 Recommendation</a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727114985"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25947e1911 class=n-a></a>Sharman JP, Farber CM, Mahadevan D, <i> et al.</i>: Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial. <i>Br J Haematol.</i> 2017; <b>176</b>(3): 412–20. <a target=xrefwindow id=d25947e1922 href="http://www.ncbi.nlm.nih.gov/pubmed/27982425">PubMed Abstract </a> | <a target=xrefwindow id=d25947e1925 href="http://dx.doi.org/10.1111/bjh.14447">Publisher Full Text </a> | <a target=xrefwindow id=d25947e1929 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5299538">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727114985">F1000 Recommendation</a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d25947e1942 class=n-a></a>Sharman JP, Brander DM, Mato A, <i> et al.</i>: Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: results of the genuine phase 3 study. <i>Hematol Oncol.</i> 2017; <b>35</b>(Supplement S2): 111–2. <a target=xrefwindow id=d25947e1953 href="http://dx.doi.org/10.1002/hon.2437_100">Publisher Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d25947e1962 class=n-a></a>Byrd JC, Pagel JM, Awan FT, <i> et al.</i>: A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. <i>Blood.</i> 2014; <b>123</b>(9): 1302–8. <a target=xrefwindow id=d25947e1973 href="http://www.ncbi.nlm.nih.gov/pubmed/24381226">PubMed Abstract </a> | <a target=xrefwindow id=d25947e1976 href="http://dx.doi.org/10.1182/blood-2013-07-512137">Publisher Full Text </a> | <a target=xrefwindow id=d25947e1980 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3938145">Free Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727112400"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25947e1989 class=n-a></a>Robak T, Hellmann A, Kloczko J, <i> et al.</i>: Randomized phase 2 study of otlertuzumab and bendamustine <i>versus</i> bendamustine in patients with relapsed chronic lymphocytic leukaemia. <i>Br J Haematol.</i> 2017; <b>176</b>(4): 618–28. <a target=xrefwindow id=d25947e2003 href="http://www.ncbi.nlm.nih.gov/pubmed/27977057">PubMed Abstract </a> | <a target=xrefwindow id=d25947e2007 href="http://dx.doi.org/10.1111/bjh.14464">Publisher Full Text </a> | <a target=xrefwindow id=d25947e2010 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5324531">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727112400">F1000 Recommendation</a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718429958"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25947e2023 class=n-a></a>Byrd JC, Brown JR, O'Brien S, <i> et al.</i>: Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. <i>N Engl J Med.</i> 2014; <b>371</b>(3): 213–23. <a target=xrefwindow id=d25947e2034 href="http://www.ncbi.nlm.nih.gov/pubmed/24881631">PubMed Abstract </a> | <a target=xrefwindow id=d25947e2037 href="http://dx.doi.org/10.1056/NEJMoa1400376">Publisher Full Text </a> | <a target=xrefwindow id=d25947e2041 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4134521">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718429958">F1000 Recommendation</a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725996669"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25947e2055 class=n-a></a>Burger JA, Tedeschi A, Barr PM, <i> et al.</i>: Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. <i>N Engl J Med.</i> 2015; <b>373</b>(25): 2425–37. <a target=xrefwindow id=d25947e2066 href="http://www.ncbi.nlm.nih.gov/pubmed/26639149">PubMed Abstract </a> | <a target=xrefwindow id=d25947e2069 href="http://dx.doi.org/10.1056/NEJMoa1509388">Publisher Full Text </a> | <a target=xrefwindow id=d25947e2073 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4722809">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725996669">F1000 Recommendation</a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726747165"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25947e2086 class=n-a></a>O'Brien S, Jones JA, Coutre SE, <i> et al.</i>: Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. <i>Lancet Oncol.</i> 2016; <b>17</b>(10): 1409–18. <a target=xrefwindow id=d25947e2097 href="http://www.ncbi.nlm.nih.gov/pubmed/27637985">PubMed Abstract </a> | <a target=xrefwindow id=d25947e2100 href="http://dx.doi.org/10.1016/S1470-2045(16)30212-1">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726747165">F1000 Recommendation</a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d25947e2113 class=n-a></a>Thompson PA, O'Brien SM, Wierda WG, <i> et al.</i>: Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. <i>Cancer.</i> 2015; <b>121</b>(20): 3612–21. <a target=xrefwindow id=d25947e2124 href="http://www.ncbi.nlm.nih.gov/pubmed/26193999">PubMed Abstract </a> | <a target=xrefwindow id=d25947e2127 href="http://dx.doi.org/10.1002/cncr.29566">Publisher Full Text </a> | <a target=xrefwindow id=d25947e2131 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4866653">Free Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d25947e2140 class=n-a></a>O'Brien SM, Furman RR, Coutre SE, <i> et al.</i>: Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia. <i>Blood.</i> 2016; <b>128</b>: 233. <a target=xrefwindow id=d25947e2151 href="http://www.bloodjournal.org/content/128/22/233/tab-article-info">Reference Source</a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d25947e2160 class=n-a></a>Byrd JC, Furman RR, Coutre SE, <i> et al.</i>: Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. <i>Blood.</i> 2015; <b>125</b>(16): 2497–506. <a target=xrefwindow id=d25947e2171 href="http://www.ncbi.nlm.nih.gov/pubmed/25700432">PubMed Abstract </a> | <a target=xrefwindow id=d25947e2174 href="http://dx.doi.org/10.1182/blood-2014-10-606038">Publisher Full Text </a> | <a target=xrefwindow id=d25947e2178 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4400288">Free Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d25947e2187 class=n-a></a>Burger JA, Montserrat E: Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling. <i>Blood.</i> 2013; <b>121</b>(9): 1501–9. <a target=xrefwindow id=d25947e2195 href="http://www.ncbi.nlm.nih.gov/pubmed/23264597">PubMed Abstract </a> | <a target=xrefwindow id=d25947e2198 href="http://dx.doi.org/10.1182/blood-2012-08-452607">Publisher Full Text </a> | <a target=xrefwindow id=d25947e2201 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4968370">Free Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727263249"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25947e2211 class=n-a></a>Burger JA, Li KW, Keating MJ, <i> et al.</i>: Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib. <i>JCI Insight.</i> 2017; <b>2</b>(2): e89904. <a target=xrefwindow id=d25947e2222 href="http://www.ncbi.nlm.nih.gov/pubmed/28138560">PubMed Abstract </a> | <a target=xrefwindow id=d25947e2225 href="http://dx.doi.org/10.1172/jci.insight.89904">Publisher Full Text </a> | <a target=xrefwindow id=d25947e2229 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5256142">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727263249">F1000 Recommendation</a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727194641"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25947e2242 class=n-a></a>Herndon TM, Chen SS, Saba NS, <i> et al.</i>: Direct <i>in vivo</i> evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood. <i>Leukemia.</i> 2017; <b>31</b>(6): 1340–7. <a target=xrefwindow id=d25947e2256 href="http://www.ncbi.nlm.nih.gov/pubmed/28074063">PubMed Abstract </a> | <a target=xrefwindow id=d25947e2260 href="http://dx.doi.org/10.1038/leu.2017.11">Publisher Full Text </a> | <a target=xrefwindow id=d25947e2263 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5462849">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727194641">F1000 Recommendation</a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d25947e2276 class=n-a></a>Cheson BD, Byrd JC, Rai KR, <i> et al.</i>: Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. <i>J Clin Oncol.</i> 2012; <b>30</b>(23): 2820–2. <a target=xrefwindow id=d25947e2287 href="http://www.ncbi.nlm.nih.gov/pubmed/22778323">PubMed Abstract </a> | <a target=xrefwindow id=d25947e2290 href="http://dx.doi.org/10.1200/JCO.2012.43.3748">Publisher Full Text </a> | <a target=xrefwindow id=d25947e2294 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3410400">Free Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718235051"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25947e2303 class=n-a></a>Woyach JA, Smucker K, Smith LL, <i> et al.</i>: Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. <i>Blood.</i> 2014; <b>123</b>(12): 1810–7. <a target=xrefwindow id=d25947e2314 href="http://www.ncbi.nlm.nih.gov/pubmed/24415539">PubMed Abstract </a> | <a target=xrefwindow id=d25947e2317 href="http://dx.doi.org/10.1182/blood-2013-09-527853">Publisher Full Text </a> | <a target=xrefwindow id=d25947e2321 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3962160">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718235051">F1000 Recommendation</a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d25947e2334 class=n-a></a>Woyach JA, Furman RR, Liu TM, <i> et al.</i>: Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. <i>N Engl J Med.</i> 2014; <b>370</b>(24): 2286–94. <a target=xrefwindow id=d25947e2345 href="http://www.ncbi.nlm.nih.gov/pubmed/24869598">PubMed Abstract </a> | <a target=xrefwindow id=d25947e2348 href="http://dx.doi.org/10.1056/NEJMoa1400029">Publisher Full Text </a> | <a target=xrefwindow id=d25947e2352 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4144824">Free Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d25947e2361 class=n-a></a>Liu TM, Woyach JA, Zhong Y, <i> et al.</i>: Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation. <i>Blood.</i> 2015; <b>126</b>(1): 61–8. <a target=xrefwindow id=d25947e2372 href="http://www.ncbi.nlm.nih.gov/pubmed/25972157">PubMed Abstract </a> | <a target=xrefwindow id=d25947e2375 href="http://dx.doi.org/10.1182/blood-2015-02-626846">Publisher Full Text </a> | <a target=xrefwindow id=d25947e2379 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4492196">Free Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d25947e2389 class=n-a></a>Cheng S, Guo A, Lu P, <i> et al.</i>: Functional characterization of BTK<sup>C481S</sup> mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors. <i>Leukemia.</i> 2015; <b>29</b>(4): 895–900. <a target=xrefwindow id=d25947e2403 href="http://www.ncbi.nlm.nih.gov/pubmed/25189416">PubMed Abstract </a> | <a target=xrefwindow id=d25947e2407 href="http://dx.doi.org/10.1038/leu.2014.263">Publisher Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726369571"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25947e2416 class=n-a></a>Burger JA, Landau DA, Taylor-Weiner A, <i> et al.</i>: Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. <i>Nat Commun.</i> 2016; <b>7</b>: 11589. <a target=xrefwindow id=d25947e2427 href="http://www.ncbi.nlm.nih.gov/pubmed/27199251">PubMed Abstract </a> | <a target=xrefwindow id=d25947e2430 href="http://dx.doi.org/10.1038/ncomms11589">Publisher Full Text </a> | <a target=xrefwindow id=d25947e2434 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4876453">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726369571">F1000 Recommendation</a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d25947e2447 class=n-a></a>Jain P, Keating M, Wierda W, <i> et al.</i>: Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. <i>Blood.</i> 2015; <b>125</b>(13): 2062–7. <a target=xrefwindow id=d25947e2458 href="http://www.ncbi.nlm.nih.gov/pubmed/25573991">PubMed Abstract </a> | <a target=xrefwindow id=d25947e2461 href="http://dx.doi.org/10.1182/blood-2014-09-603670">Publisher Full Text </a> | <a target=xrefwindow id=d25947e2465 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4467871">Free Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d25947e2474 class=n-a></a>Maddocks KJ, Ruppert AS, Lozanski G, <i> et al.</i>: Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. <i>JAMA Oncol.</i> 2015; <b>1</b>(1): 80–7. <a target=xrefwindow id=d25947e2485 href="http://www.ncbi.nlm.nih.gov/pubmed/26182309">PubMed Abstract </a> | <a target=xrefwindow id=d25947e2488 href="http://dx.doi.org/10.1001/jamaoncol.2014.218">Publisher Full Text </a> | <a target=xrefwindow id=d25947e2492 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4520535">Free Full Text </a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727289351"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25947e2501 class=n-a></a>Jain P, Thompson PA, Keating M, <i> et al.</i>: Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. <i>Cancer.</i> 2017; <b>123</b>(12): 2268–73. <a target=xrefwindow id=d25947e2512 href="http://www.ncbi.nlm.nih.gov/pubmed/28171709">PubMed Abstract </a> | <a target=xrefwindow id=d25947e2515 href="http://dx.doi.org/10.1002/cncr.30596">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727289351">F1000 Recommendation</a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d25947e2528 class=n-a></a>Jones J, Choi MY, Mato AR, <i> et al.</i>: Venetoclax (VEN) Monotherapy for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapsed after or Were Refractory to Ibrutinib or Idelalisib. <i>Blood.</i> 2016; <b>128</b>(22): 637. <a target=xrefwindow id=d25947e2539 href="http://www.bloodjournal.org/content/128/22/637">Reference Source</a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d25947e2549 class=n-a></a>Mato AR, Hill BT, Lamanna N, <i> et al.</i>: Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclax in Chronic Lymphocytic Leukemia: Results from a Multi-Center Study of 683 Patients. <i>Ann Oncol.</i> 2017; <b>28</b>(5): 1050–1056. <a target=xrefwindow id=d25947e2560 href="http://www.ncbi.nlm.nih.gov/pubmed/28171884">PubMed Abstract </a> | <a target=xrefwindow id=d25947e2563 href="http://dx.doi.org/10.1093/annonc/mdx031">Publisher Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d25947e2572 class=n-a></a>Porcu P, Flinn I, Kahl BS, <i> et al.</i>: Clinical activity of duvelisib (IPI-145), a phosphoinositide-3-kinase-δ, γ inhibitor, in patients previously treated with ibrutinib. <i>Blood.</i> 2014; <b>124</b>(21): 3335. <a target=xrefwindow id=d25947e2583 href="http://www.bloodjournal.org/content/124/21/3335?sso-checked=true">Reference Source</a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d25947e2592 class=n-a></a>Sharman JP, Shustov AR, Smith MR, <i> et al.</i>: Updated Results on the Clinical Activity of Entospletinib (GS-9973), a Selective Syk Inhibitor, in Patients with CLL Previously Treated with an Inhibitor of the B-Cell Receptor Signaling Pathway. <i>Blood.</i> 2016; <b>128</b>(22): 3225. <a target=xrefwindow id=d25947e2603 href="http://www.bloodjournal.org/content/128/22/3225?sso-checked=true">Reference Source</a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d25947e2612 class=n-a></a>El-Gamal D, Williams K, LaFollette TD, <i> et al.</i>: PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL. <i>Blood.</i> 2014; <b>124</b>(9): 1481–91. <a target=xrefwindow id=d25947e2623 href="http://www.ncbi.nlm.nih.gov/pubmed/25001469">PubMed Abstract </a> | <a target=xrefwindow id=d25947e2626 href="http://dx.doi.org/10.1182/blood-2014-05-574830">Publisher Full Text </a> | <a target=xrefwindow id=d25947e2630 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4148770">Free Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d25947e2639 class=n-a></a>Kopp N, Tschuri S, Haebe S, <i> et al.</i>: Newer-generation HSP90 inhibitors can overcome ibrutinib resistance and suppress proliferation in human mantle cell lymphoma <i>in vitro</i> and <i>in vivo</i>. <i>Blood.</i> 2014; <b>124</b>(21): 1686. <a target=xrefwindow id=d25947e2657 href="http://www.bloodjournal.org/content/124/21/1686">Reference Source</a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725419659"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25947e2666 class=n-a></a>Hing ZA, Mantel R, Beckwith KA, <i> et al.</i>: Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia. <i>Blood.</i> 2015; <b>125</b>(20): 3128–32. <a target=xrefwindow id=d25947e2677 href="http://www.ncbi.nlm.nih.gov/pubmed/25838351">PubMed Abstract </a> | <a target=xrefwindow id=d25947e2680 href="http://dx.doi.org/10.1182/blood-2015-01-621391">Publisher Full Text </a> | <a target=xrefwindow id=d25947e2684 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4432007">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725419659">F1000 Recommendation</a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d25947e2698 class=n-a></a>Neuman LL, Ward R, Arnold D, <i> et al.</i>: First-in-Human Phase 1a Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Noncovalent Bruton Tyrosine Kinase (BTK) Inhibitor SNS-062 in Healthy Subjects. <i>Blood.</i> 2016; <b>128</b>(22): 2032. <a target=xrefwindow id=d25947e2709 href="http://www.bloodjournal.org/content/128/22/2032">Reference Source</a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d25947e2718 class=n-a></a>Reiff S, Guinn D, Mantel R, <i> et al.</i>: Evaluation of the novel Bruton's tyrosinekinase (BTK) inhibitor GDC-0853 in chronic lymphocytic leukemia (CLL) with wildtype or C481S mutated BTK. <i>J Clin Oncol.</i> 2016; 3–7. <a target=xrefwindow id=d25947e2726 href="http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.7530">Reference Source</a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d25947e2735 class=n-a></a>Reiff SD, Mantel R, Smith LL, <i> et al.</i>: The Bruton's Tyrosine Kinase (BTK) Inhibitor ARQ 531 Effectively Inhibits Wild Type and C481S Mutant BTK and Is Superior to Ibrutinib in a Mouse Model of Chronic Lymphocytic Leukemia. <i>Blood.</i> 2016; <b>128</b>(22): 3232. <a target=xrefwindow id=d25947e2746 href="http://www.bloodjournal.org/content/128/22/3232">Reference Source</a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d25947e2755 class=n-a></a>Woyach JA, Bojnik E, Ruppert AS, <i> et al.</i>: Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL). <i>Blood.</i> 2014; <b>123</b>(8): 1207–13. <a target=xrefwindow id=d25947e2766 href="http://www.ncbi.nlm.nih.gov/pubmed/24311722">PubMed Abstract </a> | <a target=xrefwindow id=d25947e2769 href="http://dx.doi.org/10.1182/blood-2013-07-515361">Publisher Full Text </a> | <a target=xrefwindow id=d25947e2773 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3931190">Free Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d25947e2782 class=n-a></a>Honigberg LA, Smith AM, Sirisawad M, <i> et al.</i>: The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. <i>Proc Natl Acad Sci U S A.</i> 2010; <b>107</b>(29): 13075–80. <a target=xrefwindow id=d25947e2793 href="http://www.ncbi.nlm.nih.gov/pubmed/20615965">PubMed Abstract </a> | <a target=xrefwindow id=d25947e2796 href="http://dx.doi.org/10.1073/pnas.1004594107">Publisher Full Text </a> | <a target=xrefwindow id=d25947e2800 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2919935">Free Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d25947e2809 class=n-a></a>McMullen JR, Boey EJ, Ooi JY, <i> et al.</i>: Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. <i>Blood.</i> 2014; <b>124</b>(25): 3829–30. <a target=xrefwindow id=d25947e2820 href="http://www.ncbi.nlm.nih.gov/pubmed/25498454">PubMed Abstract </a> | <a target=xrefwindow id=d25947e2823 href="http://dx.doi.org/10.1182/blood-2014-10-604272">Publisher Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d25947e2833 class=n-a></a>Levade M, David E, Garcia C, <i> et al.</i>: Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. <i>Blood.</i> 2014; <b>124</b>(26): 3991–5. <a target=xrefwindow id=d25947e2844 href="http://www.ncbi.nlm.nih.gov/pubmed/25305202">PubMed Abstract </a> | <a target=xrefwindow id=d25947e2847 href="http://dx.doi.org/10.1182/blood-2014-06-583294">Publisher Full Text </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d25947e2856 class=n-a></a>Kamel S, Horton L, Ysebaert L, <i> et al.</i>: Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. <i>Leukemia.</i> 2015; <b>29</b>(4): 783–7. <a target=xrefwindow id=d25947e2867 href="http://www.ncbi.nlm.nih.gov/pubmed/25138588">PubMed Abstract </a> | <a target=xrefwindow id=d25947e2870 href="http://dx.doi.org/10.1038/leu.2014.247">Publisher Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d25947e2879 class=n-a></a>Alberelli MA, Innocenti I, Sica S, <i> et al.</i>: PO-54 - Clinical and laboratory characterization of platelet dysfunction caused by ibrutinib treatment in patients with chronic lymphocytic leukemia. <i>Thromb Res.</i> 2016; <b>140 Suppl 1</b>: S196. <a target=xrefwindow id=d25947e2890 href="http://www.ncbi.nlm.nih.gov/pubmed/27161742">PubMed Abstract </a> | <a target=xrefwindow id=d25947e2893 href="http://dx.doi.org/10.1016/S0049-3848(16)30187-6">Publisher Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d25947e2902 class=n-a></a>Patel V, Balakrishnan K, Bibikova E, <i> et al.</i>: Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells. <i>Clin Cancer Res.</i> 2017; <b>23</b>(14): 3734–43. <a target=xrefwindow id=d25947e2913 href="http://www.ncbi.nlm.nih.gov/pubmed/28034907">PubMed Abstract </a> | <a target=xrefwindow id=d25947e2916 href="http://dx.doi.org/10.1158/1078-0432.CCR-16-1446">Publisher Full Text </a> | <a target=xrefwindow id=d25947e2920 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5491371">Free Full Text </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725996533"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25947e2929 class=n-a></a>Byrd JC, Harrington B, O'Brien S, <i> et al.</i>: Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. <i>N Engl J Med.</i> 2016; <b>374</b>(4): 323–32. <a target=xrefwindow id=d25947e2940 href="http://www.ncbi.nlm.nih.gov/pubmed/26641137">PubMed Abstract </a> | <a target=xrefwindow id=d25947e2943 href="http://dx.doi.org/10.1056/NEJMoa1509981">Publisher Full Text </a> | <a target=xrefwindow id=d25947e2947 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4862586">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725996533">F1000 Recommendation</a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d25947e2960 class=n-a></a>Walter HS, Jayne S, Rule SA, <i> et al.</i>: Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059. <i>Blood.</i> 2017; <b>129</b>(20): 2808–10. <a target=xrefwindow id=d25947e2971 href="http://www.ncbi.nlm.nih.gov/pubmed/28377400">PubMed Abstract </a> | <a target=xrefwindow id=d25947e2974 href="http://dx.doi.org/10.1182/blood-2017-02-765115">Publisher Full Text </a> | <a target=xrefwindow id=d25947e2978 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5437828">Free Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d25947e2988 class=n-a></a>Tam C, Grigg AP, Opat S, <i> et al.</i>: The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial. <i>Blood.</i> 2015; <b>126</b>(23): 832. <a target=xrefwindow id=d25947e2999 href="http://www.bloodjournal.org/content/126/23/832">Reference Source</a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d25947e3008 class=n-a></a>Tam CS, Opat S, Cull G, <i> et al.</i>: Twice Daily Dosing with the Highly Specific BTK Inhibitor, Bgb-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated with Durable Responses in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL). <i>Blood.</i> 2016; <b>128</b>(22): 642. <a target=xrefwindow id=d25947e3019 href="http://www.bloodjournal.org/content/128/22/642">Reference Source</a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d25947e3028 class=n-a></a>Bose P, Gandhi VV, Keating MJ: Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses. <i>Expert Opin Drug Metab Toxicol.</i> 2016; 1–12. <a target=xrefwindow id=d25947e3033 href="http://www.ncbi.nlm.nih.gov/pubmed/27686109">PubMed Abstract </a> | <a target=xrefwindow id=d25947e3036 href="http://dx.doi.org/10.1080/17425255.2016.1239717">Publisher Full Text </a> | <a target=xrefwindow id=d25947e3039 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5391303">Free Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717959990"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25947e3048 class=n-a></a>Advani RH, Buggy JJ, Sharman JP, <i> et al.</i>: Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. <i>J Clin Oncol.</i> 2013; <b>31</b>(1): 88–94. <a target=xrefwindow id=d25947e3059 href="http://www.ncbi.nlm.nih.gov/pubmed/23045577">PubMed Abstract </a> | <a target=xrefwindow id=d25947e3062 href="http://dx.doi.org/10.1200/JCO.2012.42.7906">Publisher Full Text </a> | <a target=xrefwindow id=d25947e3066 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5505166">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717959990">F1000 Recommendation</a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a name=d25947e3079 class=n-a></a>Chen SS, Chang BY, Chang S, <i> et al.</i>: BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia. <i>Leukemia.</i> 2016; <b>30</b>(4): 833–43. <a target=xrefwindow id=d25947e3090 href="http://www.ncbi.nlm.nih.gov/pubmed/26582643">PubMed Abstract </a> | <a target=xrefwindow id=d25947e3093 href="http://dx.doi.org/10.1038/leu.2015.316">Publisher Full Text </a> | <a target=xrefwindow id=d25947e3097 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4832074">Free Full Text </a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a name=d25947e3106 class=n-a></a>Cervantes-Gomez F, Kumar Patel V, Bose P, <i> et al.</i>: Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes. <i>Leukemia.</i> 2016; <b>30</b>(8): 1803–4. <a target=xrefwindow id=d25947e3117 href="http://www.ncbi.nlm.nih.gov/pubmed/27198052">PubMed Abstract </a> | <a target=xrefwindow id=d25947e3120 href="http://dx.doi.org/10.1038/leu.2016.129">Publisher Full Text </a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727339088"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25947e3130 class=n-a></a>Mato AR, Timlin C, Ujjani C, <i> et al.</i>: Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced-dose ibrutinib: results from a multi-centre study. <i>Br J Haematol.</i> 2017. <a target=xrefwindow id=d25947e3138 href="http://www.ncbi.nlm.nih.gov/pubmed/28220935">PubMed Abstract </a> | <a target=xrefwindow id=d25947e3141 href="http://dx.doi.org/10.1111/bjh.14540">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727339088">F1000 Recommendation</a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727475767"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25947e3154 class=n-a></a>Barr PM, Brown JR, Hillmen P, <i> et al.</i>: Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. <i>Blood.</i> 2017; <b>129</b>(19): 2612–5. <a target=xrefwindow id=d25947e3165 href="http://www.ncbi.nlm.nih.gov/pubmed/28373262">PubMed Abstract </a> | <a target=xrefwindow id=d25947e3168 href="http://dx.doi.org/10.1182/blood-2016-12-737346">Publisher Full Text </a> | <a target=xrefwindow id=d25947e3172 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5437732">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727475767">F1000 Recommendation</a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a name=d25947e3185 class=n-a></a>Burger JA, Keating MJ, Wierda WG, <i> et al.</i>: Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. <i>Lancet Oncol.</i> 2014; <b>15</b>(10): 1090–9. <a target=xrefwindow id=d25947e3196 href="http://www.ncbi.nlm.nih.gov/pubmed/25150798">PubMed Abstract </a> | <a target=xrefwindow id=d25947e3199 href="http://dx.doi.org/10.1016/S1470-2045(14)70335-3">Publisher Full Text </a> | <a target=xrefwindow id=d25947e3203 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4174348">Free Full Text </a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a name=d25947e3212 class=n-a></a>Jaglowski SM, Jones JA, Nagar V, <i> et al.</i>: Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. <i>Blood.</i> 2015; <b>126</b>(7): 842–50. <a target=xrefwindow id=d25947e3223 href="http://www.ncbi.nlm.nih.gov/pubmed/26116658">PubMed Abstract </a> | <a target=xrefwindow id=d25947e3226 href="http://dx.doi.org/10.1182/blood-2014-12-617522">Publisher Full Text </a> | <a target=xrefwindow id=d25947e3230 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4536539">Free Full Text </a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d25947e3239 class=n-a></a>Kohrt HE, Sagiv-Barfi I, Rafiq S, <i> et al.</i>: Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. <i>Blood.</i> 2014; <b>123</b>(12): 1957–60. <a target=xrefwindow id=d25947e3250 href="http://www.ncbi.nlm.nih.gov/pubmed/24652965">PubMed Abstract </a> | <a target=xrefwindow id=d25947e3253 href="http://dx.doi.org/10.1182/blood-2014-01-547869">Publisher Full Text </a> | <a target=xrefwindow id=d25947e3257 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3962169">Free Full Text </a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726009690"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25947e3266 class=n-a></a>Chanan-Khan A, Cramer P, Demirkan F, <i> et al.</i>: Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. <i>Lancet Oncol.</i> 2016; <b>17</b>(2): 200–11. <a target=xrefwindow id=d25947e3277 href="http://www.ncbi.nlm.nih.gov/pubmed/26655421">PubMed Abstract </a> | <a target=xrefwindow id=d25947e3280 href="http://dx.doi.org/10.1016/S1470-2045(15)00465-9">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726009690">F1000 Recommendation</a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a name=d25947e3294 class=n-a></a>Furman RR, Sharman JP, Coutre SE, <i> et al.</i>: Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. <i>N Engl J Med.</i> 2014; <b>370</b>(11): 997–1007. <a target=xrefwindow id=d25947e3305 href="http://www.ncbi.nlm.nih.gov/pubmed/24450857">PubMed Abstract </a> | <a target=xrefwindow id=d25947e3308 href="http://dx.doi.org/10.1056/NEJMoa1315226">Publisher Full Text </a> | <a target=xrefwindow id=d25947e3312 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4161365">Free Full Text </a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a name=d25947e3321 class=n-a></a>Yang Q, Chen LS, Ha MJ, <i> et al.</i>: Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma. <i>Clin Cancer Res.</i> 2017; <b>23</b>(1): 181–92. <a target=xrefwindow id=d25947e3332 href="http://www.ncbi.nlm.nih.gov/pubmed/27342398">PubMed Abstract </a> | <a target=xrefwindow id=d25947e3335 href="http://dx.doi.org/10.1158/1078-0432.CCR-15-3135">Publisher Full Text </a> | <a target=xrefwindow id=d25947e3339 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5433851">Free Full Text </a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a name=d25947e3348 class=n-a></a>Modi P, Balakrishnan K, Yang Q, <i> et al.</i>: Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells. <i>Oncotarget.</i> 2017; <b>8</b>(10): 16259–74. <a target=xrefwindow id=d25947e3359 href="http://www.ncbi.nlm.nih.gov/pubmed/28187444">PubMed Abstract </a> | <a target=xrefwindow id=d25947e3362 href="http://dx.doi.org/10.18632/oncotarget.15180">Publisher Full Text </a> | <a target=xrefwindow id=d25947e3366 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5369961">Free Full Text </a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727253578"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25947e3375 class=n-a></a>Zelenetz AD, Barrientos JC, Brown JR, <i> et al.</i>: Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet Oncol.</i> 2017; <b>18</b>(3): 297–311. <a target=xrefwindow id=d25947e3386 href="http://www.ncbi.nlm.nih.gov/pubmed/28139405">PubMed Abstract </a> | <a target=xrefwindow id=d25947e3389 href="http://dx.doi.org/10.1016/S1470-2045(16)30671-4">Publisher Full Text </a> | <a target=xrefwindow id=d25947e3393 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5589180">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727253578">F1000 Recommendation</a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727373020"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25947e3406 class=n-a></a>Jones JA, Robak T, Brown JR, <i> et al.</i>: Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. <i>Lancet Haematol.</i> 2017; <b>4</b>(3): e114–e126. <a target=xrefwindow id=d25947e3417 href="http://www.ncbi.nlm.nih.gov/pubmed/28257752">PubMed Abstract </a> | <a target=xrefwindow id=d25947e3420 href="http://dx.doi.org/10.1016/S2352-3026(17)30019-4">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727373020">F1000 Recommendation</a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726392645"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25947e3433 class=n-a></a>Lampson BL, Kasar SN, Matos TR, <i> et al.</i>: Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. <i>Blood.</i> 2016; <b>128</b>(2): 195–203. <a target=xrefwindow id=d25947e3444 href="http://www.ncbi.nlm.nih.gov/pubmed/27247136">PubMed Abstract </a> | <a target=xrefwindow id=d25947e3447 href="http://dx.doi.org/10.1182/blood-2016-03-707133">Publisher Full Text </a> | <a target=xrefwindow id=d25947e3451 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4946200">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726392645">F1000 Recommendation</a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727303705"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25947e3465 class=n-a></a>Compagno M, Wang Q, Pighi C, <i> et al.</i>: Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells. <i>Nature.</i> 2017; <b>542</b>(7642): 489–93. <a target=xrefwindow id=d25947e3476 href="http://www.ncbi.nlm.nih.gov/pubmed/28199309">PubMed Abstract </a> | <a target=xrefwindow id=d25947e3479 href="http://dx.doi.org/10.1038/nature21406">Publisher Full Text </a> | <a target=xrefwindow id=d25947e3483 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5382874">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727303705">F1000 Recommendation</a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a name=d25947e3496 class=n-a></a>Vangapandu HV, Jain N, Gandhi V: Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia. <i>Expert Opin Investig Drugs.</i> 2017; <b>26</b>(5): 625–32. <a target=xrefwindow id=d25947e3504 href="http://www.ncbi.nlm.nih.gov/pubmed/28388280">PubMed Abstract </a> | <a target=xrefwindow id=d25947e3507 href="http://dx.doi.org/10.1080/13543784.2017.1312338">Publisher Full Text </a> | <a target=xrefwindow id=d25947e3510 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5584596">Free Full Text </a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a name=d25947e3519 class=n-a></a>Balakrishnan K, Peluso M, Fu M, <i> et al.</i>: The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL. <i>Leukemia.</i> 2015; <b>29</b>(9): 1811–22. <a target=xrefwindow id=d25947e3530 href="http://www.ncbi.nlm.nih.gov/pubmed/25917267">PubMed Abstract </a> | <a target=xrefwindow id=d25947e3533 href="http://dx.doi.org/10.1038/leu.2015.105">Publisher Full Text </a> | <a target=xrefwindow id=d25947e3537 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4558374">Free Full Text </a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a name=d25947e3546 class=n-a></a>Dong S, Guinn D, Dubovsky JA, <i> et al.</i>: IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells. <i>Blood.</i> 2014; <b>124</b>(24): 3583–6. <a target=xrefwindow id=d25947e3557 href="http://www.ncbi.nlm.nih.gov/pubmed/25258342">PubMed Abstract </a> | <a target=xrefwindow id=d25947e3560 href="http://dx.doi.org/10.1182/blood-2014-07-587279">Publisher Full Text </a> | <a target=xrefwindow id=d25947e3564 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4256910">Free Full Text </a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a name=d25947e3573 class=n-a></a>O'Brien S, Patel M, Kahl BS, <i> et al.</i>: Duvelisib (IPI-145), a PI3K-δ, γ inhibitor, is clinically active in patients with relapsed/refractory chronic lymphocytic leukemia. <i>Blood.</i> 2014; <b>124</b>(21): 3334. <a target=xrefwindow id=d25947e3584 href="http://www.bloodjournal.org/content/124/21/3334">Reference Source</a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a name=d25947e3593 class=n-a></a>Patel MR, O'Brien SM, Faia K, <i> et al.</i>: Early clinical activity and pharmacodynamic effects of duvelisib, a PI3K-δ,γ inhibitor, in patients with treatment-naïve CLL. <i>J Clin Oncol.</i> 2015; <b>33</b>: 7074. <a target=xrefwindow id=d25947e3604 href="http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.7074">Reference Source</a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a name=d25947e3614 class=n-a></a>Flinn IW, Cherry M, Maris M, <i> et al.</i>: Combination trial of duvelisib (IPI-145) with bendamustine, rituximab, or bendamustine/rituximab in patients with lymphoma or chronic lymphocytic leukemia. <i>Blood.</i> 2015; <b>126</b>(23): 3928. <a target=xrefwindow id=d25947e3625 href="http://www.bloodjournal.org/content/126/23/3928?sso-checked=true">Reference Source</a></span></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a name=d25947e3634 class=n-a></a>Davids MS, Kim HT, Gilbert E, <i> et al.</i>: Preliminary results of a phase Ib study of duvelisib in combination with FCR (dFCR) in previously untreated, younger patients with CLL. <i>Blood.</i> 2015; <b>126</b>(23): 4158. <a target=xrefwindow id=d25947e3645 href="http://www.bloodjournal.org/content/126/23/4158">Reference Source</a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726814834"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25947e3654 class=n-a></a>Kwok M, Rawstron AC, Varghese A, <i> et al.</i>: Minimal residual disease is an independent predictor for 10-year survival in CLL. <i>Blood.</i> 2016; <b>128</b>(24): 2770–3. <a target=xrefwindow id=d25947e3665 href="http://www.ncbi.nlm.nih.gov/pubmed/27697770">PubMed Abstract </a> | <a target=xrefwindow id=d25947e3668 href="http://dx.doi.org/10.1182/blood-2016-05-714162">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726814834">F1000 Recommendation</a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1066064"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25947e3681 class=n-a></a>Del Gaizo Moore V, Brown JR, Certo M, <i> et al.</i>: Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. <i>J Clin Invest.</i> 2007; <b>117</b>(1): 112–21. <a target=xrefwindow id=d25947e3692 href="http://www.ncbi.nlm.nih.gov/pubmed/17200714">PubMed Abstract </a> | <a target=xrefwindow id=d25947e3695 href="http://dx.doi.org/10.1172/JCI28281">Publisher Full Text </a> | <a target=xrefwindow id=d25947e3699 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1716201">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1066064">F1000 Recommendation</a></span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a name=d25947e3712 class=n-a></a>Roberts AW, Seymour JF, Brown JR, <i> et al.</i>: Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. <i>J Clin Oncol.</i> 2012; <b>30</b>(5): 488–96. <a target=xrefwindow id=d25947e3723 href="http://www.ncbi.nlm.nih.gov/pubmed/22184378">PubMed Abstract </a> | <a target=xrefwindow id=d25947e3726 href="http://dx.doi.org/10.1200/JCO.2011.34.7898">Publisher Full Text </a> | <a target=xrefwindow id=d25947e3730 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4979082">Free Full Text </a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1071045"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25947e3739 class=n-a></a>Mason KD, Carpinelli MR, Fletcher JI, <i> et al.</i>: Programmed anuclear cell death delimits platelet life span. <i>Cell.</i> 2007; <b>128</b>(6): 1173–86. <a target=xrefwindow id=d25947e3750 href="http://www.ncbi.nlm.nih.gov/pubmed/17382885">PubMed Abstract </a> | <a target=xrefwindow id=d25947e3753 href="http://dx.doi.org/10.1016/j.cell.2007.01.037">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1071045">F1000 Recommendation</a></span></li><li><a name=ref-102 class=n-a></a><span class=label>102. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717973247"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25947e3767 class=n-a></a>Souers AJ, Leverson JD, Boghaert ER, <i> et al.</i>: ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. <i>Nat Med.</i> 2013; <b>19</b>(2): 202–8. <a target=xrefwindow id=d25947e3778 href="http://www.ncbi.nlm.nih.gov/pubmed/23291630">PubMed Abstract </a> | <a target=xrefwindow id=d25947e3781 href="http://dx.doi.org/10.1038/nm.3048">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717973247">F1000 Recommendation</a></span></li><li><a name=ref-103 class=n-a></a><span class=label>103. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725994198"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25947e3794 class=n-a></a>Roberts AW, Davids MS, Pagel JM, <i> et al.</i>: Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. <i>N Engl J Med.</i> 2016; <b>374</b>(4): 311–22. <a target=xrefwindow id=d25947e3805 href="http://www.ncbi.nlm.nih.gov/pubmed/26639348">PubMed Abstract </a> | <a target=xrefwindow id=d25947e3808 href="http://dx.doi.org/10.1056/NEJMoa1513257">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725994198">F1000 Recommendation</a></span></li><li><a name=ref-104 class=n-a></a><span class=label>104. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726356653"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25947e3821 class=n-a></a>Stilgenbauer S, Eichhorst B, Schetelig J, <i> et al.</i>: Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. <i>Lancet Oncol.</i> 2016; <b>17</b>(6): 768–78. <a target=xrefwindow id=d25947e3832 href="http://www.ncbi.nlm.nih.gov/pubmed/27178240">PubMed Abstract </a> | <a target=xrefwindow id=d25947e3835 href="http://dx.doi.org/10.1016/S1470-2045(16)30019-5">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726356653">F1000 Recommendation</a></span></li><li><a name=ref-105 class=n-a></a><span class=label>105. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727212446"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25947e3848 class=n-a></a>Seymour JF, Ma S, Brander DM, <i> et al.</i>: Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. <i>Lancet Oncol.</i> 2017; <b>18</b>(2): 230–40. <a target=xrefwindow id=d25947e3859 href="http://www.ncbi.nlm.nih.gov/pubmed/28089635">PubMed Abstract </a> | <a target=xrefwindow id=d25947e3862 href="http://dx.doi.org/10.1016/S1470-2045(17)30012-8">Publisher Full Text </a> | <a target=xrefwindow id=d25947e3866 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5316338">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727212446">F1000 Recommendation</a></span></li><li><a name=ref-106 class=n-a></a><span class=label>106. </span>&nbsp;<span class=citation><a name=d25947e3879 class=n-a></a>Thompson PA, Tam CS, O'Brien SM, <i> et al.</i>: Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in <i>IGHV</i>-mutated chronic lymphocytic leukemia. <i>Blood.</i> 2016; <b>127</b>(3): 303–9. <a target=xrefwindow id=d25947e3893 href="http://www.ncbi.nlm.nih.gov/pubmed/26492934">PubMed Abstract </a> | <a target=xrefwindow id=d25947e3897 href="http://dx.doi.org/10.1182/blood-2015-09-667675">Publisher Full Text </a> | <a target=xrefwindow id=d25947e3900 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4760129">Free Full Text </a></span></li><li><a name=ref-107 class=n-a></a><span class=label>107. </span>&nbsp;<span class=citation><a name=d25947e3909 class=n-a></a>Davids MS, Kim HT, Brander DM, <i> et al.</i>: Initial Results of a Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients. <i>Blood.</i> 2016; <b>128</b>(22): 3243. <a target=xrefwindow id=d25947e3920 href="http://www.bloodjournal.org/content/128/22/3243?sso-checked=true">Reference Source</a></span></li><li><a name=ref-108 class=n-a></a><span class=label>108. </span>&nbsp;<span class=citation><a name=d25947e3930 class=n-a></a>Benjamini O, Jain P, Trinh L, <i> et al.</i>: Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. <i>Leuk Lymphoma.</i> 2015; <b>56</b>(6): 1643–50. <a target=xrefwindow id=d25947e3941 href="http://www.ncbi.nlm.nih.gov/pubmed/25308294">PubMed Abstract </a> | <a target=xrefwindow id=d25947e3944 href="http://dx.doi.org/10.3109/10428194.2014.957203">Publisher Full Text </a> | <a target=xrefwindow id=d25947e3948 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4437921">Free Full Text </a></span></li><li><a name=ref-109 class=n-a></a><span class=label>109. </span>&nbsp;<span class=citation><a name=d25947e3957 class=n-a></a>Jain N, Thompson PA, Burger JA, <i> et al.</i>: Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (GA101) (iFCG) for previously untreated patients with chronic lymphocytic leukemia (CLL) with mutated IGHV and non-del (17p). <i>J Clin Oncol.</i> 2017; <b>35</b>: 7522. <a target=xrefwindow id=d25947e3968 href="http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.7522">Reference Source</a></span></li><li><a name=ref-110 class=n-a></a><span class=label>110. </span>&nbsp;<span class=citation><a name=d25947e3977 class=n-a></a>Thompson PA, Wierda WG: Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL. <i>Blood.</i> 2016; <b>127</b>(3): 279–86. <a target=xrefwindow id=d25947e3985 href="http://www.ncbi.nlm.nih.gov/pubmed/26576865">PubMed Abstract </a> | <a target=xrefwindow id=d25947e3988 href="http://dx.doi.org/10.1182/blood-2015-08-634816">Publisher Full Text </a> | <a target=xrefwindow id=d25947e3991 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4828075">Free Full Text </a></span></li><li><a name=ref-111 class=n-a></a><span class=label>111. </span>&nbsp;<span class=citation><a name=d25947e4000 class=n-a></a>Cervantes-Gomez F, Lamothe B, Woyach JA, <i> et al.</i>: Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia. <i>Clin Cancer Res.</i> 2015; <b>21</b>(16): 3705–15. <a target=xrefwindow id=d25947e4011 href="http://www.ncbi.nlm.nih.gov/pubmed/25829398">PubMed Abstract </a> | <a target=xrefwindow id=d25947e4014 href="http://dx.doi.org/10.1158/1078-0432.CCR-14-2809">Publisher Full Text </a> | <a target=xrefwindow id=d25947e4018 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4537801">Free Full Text </a></span></li><li><a name=ref-112 class=n-a></a><span class=label>112. </span>&nbsp;<span class=citation><a name=d25947e4027 class=n-a></a>Deng J, Isik E, Fernandes SM, <i> et al.</i>: Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia. <i>Leukemia.</i> 2017; <b>31</b>(10): 2075–2084. <a target=xrefwindow id=d25947e4038 href="http://www.ncbi.nlm.nih.gov/pubmed/28111464">PubMed Abstract </a> | <a target=xrefwindow id=d25947e4041 href="http://dx.doi.org/10.1038/leu.2017.32">Publisher Full Text </a> | <a target=xrefwindow id=d25947e4045 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5555835">Free Full Text </a></span></li><li><a name=ref-113 class=n-a></a><span class=label>113. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718021374"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25947e4054 class=n-a></a>Byrd JC, Furman RR, Coutre SE, <i> et al.</i>: Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. <i>N Engl J Med.</i> 2013; <b>369</b>(1): 32–42. <a target=xrefwindow id=d25947e4065 href="http://www.ncbi.nlm.nih.gov/pubmed/23782158">PubMed Abstract </a> | <a target=xrefwindow id=d25947e4068 href="http://dx.doi.org/10.1056/NEJMoa1215637">Publisher Full Text </a> | <a target=xrefwindow id=d25947e4072 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3772525">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718021374">F1000 Recommendation</a></span></li><li><a name=ref-114 class=n-a></a><span class=label>114. </span>&nbsp;<span class=citation><a name=d25947e4086 class=n-a></a>Jones JA, Woyach J, Awan FT, <i> et al.</i>: Phase 1b Results of a Phase 1b/2 Study of Obinutuzmab, Ibrutinib, and Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood.</i> 2016; <b>128</b>(22): 639. <a target=xrefwindow id=d25947e4097 href="http://www.bloodjournal.org/content/128/22/639?sso-checked=true">Reference Source</a></span></li><li><a name=ref-115 class=n-a></a><span class=label>115. </span>&nbsp;<span class=citation><a name=d25947e4106 class=n-a></a>Chen Q, Jain N, Ayer T, <i> et al.</i>: Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States. <i>J Clin Oncol.</i> 2017; <b>35</b>(2): 166–74. <a target=xrefwindow id=d25947e4117 href="http://www.ncbi.nlm.nih.gov/pubmed/27870563">PubMed Abstract </a> | <a target=xrefwindow id=d25947e4120 href="http://dx.doi.org/10.1200/JCO.2016.68.2856">Publisher Full Text </a> | <a target=xrefwindow id=d25947e4124 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5559889">Free Full Text </a></span></li><li><a name=ref-116 class=n-a></a><span class=label>116. </span>&nbsp;<span class=citation><a name=d25947e4133 class=n-a></a>Patel VM, Balakrishnan K, Douglas M, <i> et al.</i>: Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199). <i>Leukemia.</i> 2017; <b>31</b>(9): 1872–81. <a target=xrefwindow id=d25947e4144 href="http://www.ncbi.nlm.nih.gov/pubmed/28017967">PubMed Abstract </a> | <a target=xrefwindow id=d25947e4147 href="http://dx.doi.org/10.1038/leu.2016.382">Publisher Full Text </a> | <a target=xrefwindow id=d25947e4151 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5540815">Free Full Text </a></span></li><li><a name=ref-117 class=n-a></a><span class=label>117. </span>&nbsp;<span class=citation><a name=d25947e4160 class=n-a></a>Ding W, LaPlant BR, Call TG, <i> et al.</i>: Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. <i>Blood.</i> 2017; <b>129</b>(26): 3419–3427. <a target=xrefwindow id=d25947e4171 href="http://www.ncbi.nlm.nih.gov/pubmed/28424162">PubMed Abstract </a> | <a target=xrefwindow id=d25947e4174 href="http://dx.doi.org/10.1182/blood-2017-02-765685">Publisher Full Text </a> | <a target=xrefwindow id=d25947e4178 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5492091">Free Full Text </a></span></li><li><a name=ref-118 class=n-a></a><span class=label>118. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725372046"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25947e4187 class=n-a></a>Sagiv-Barfi I, Kohrt HEK, Czerwinski DK, <i> et al.</i>: Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. <i>Proc Natl Acad Sci U S A.</i> 2015; <b>112</b>(9): E966–72. <a target=xrefwindow id=d25947e4198 href="http://www.ncbi.nlm.nih.gov/pubmed/25730880">PubMed Abstract </a> | <a target=xrefwindow id=d25947e4201 href="http://dx.doi.org/10.1073/pnas.1500712112">Publisher Full Text </a> | <a target=xrefwindow id=d25947e4205 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4352777">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725372046">F1000 Recommendation</a></span></li><li><a name=ref-119 class=n-a></a><span class=label>119. </span>&nbsp;<span class=citation><a name=d25947e4218 class=n-a></a>Dubovsky JA, Beckwith KA, Natarajan G, <i> et al.</i>: Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. <i>Blood.</i> 2013; <b>122</b>(15): 2539–49. <a target=xrefwindow id=d25947e4229 href="http://www.ncbi.nlm.nih.gov/pubmed/23886836">PubMed Abstract </a> | <a target=xrefwindow id=d25947e4232 href="http://dx.doi.org/10.1182/blood-2013-06-507947">Publisher Full Text </a> | <a target=xrefwindow id=d25947e4236 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3795457">Free Full Text </a></span></li><li><a name=ref-120 class=n-a></a><span class=label>120. </span>&nbsp;<span class=citation><a name=d25947e4246 class=n-a></a>Bose P, Gandhi V, Konopleva M: Pathways and mechanisms of venetoclax resistance. <i>Leuk Lymphoma.</i> 2017; <b>58</b>(9): 1–17. <a target=xrefwindow id=d25947e4254 href="http://www.ncbi.nlm.nih.gov/pubmed/28140720">PubMed Abstract </a> | <a target=xrefwindow id=d25947e4257 href="http://dx.doi.org/10.1080/10428194.2017.1283032">Publisher Full Text </a> | <a target=xrefwindow id=d25947e4260 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5478500">Free Full Text </a></span></li><li><a name=ref-121 class=n-a></a><span class=label>121. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725314829"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25947e4269 class=n-a></a>Leverson JD, Zhang H, Chen J, <i> et al.</i>: Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). <i>Cell Death Dis.</i> 2015; <b>6</b>: e1590. <a target=xrefwindow id=d25947e4280 href="http://www.ncbi.nlm.nih.gov/pubmed/25590800">PubMed Abstract </a> | <a target=xrefwindow id=d25947e4283 href="http://dx.doi.org/10.1038/cddis.2014.561">Publisher Full Text </a> | <a target=xrefwindow id=d25947e4287 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4669759">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725314829">F1000 Recommendation</a></span></li><li><a name=ref-122 class=n-a></a><span class=label>122. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727063704"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25947e4300 class=n-a></a>Lee T, Bian Z, Zhao B, <i> et al.</i>: Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitors. <i>FEBS Lett.</i> 2017; <b>591</b>(1): 240–51. <a target=xrefwindow id=d25947e4311 href="http://www.ncbi.nlm.nih.gov/pubmed/27878989">PubMed Abstract </a> | <a target=xrefwindow id=d25947e4314 href="http://dx.doi.org/10.1002/1873-3468.12497">Publisher Full Text </a> | <a target=xrefwindow id=d25947e4318 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5381274">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727063704">F1000 Recommendation</a></span></li><li><a name=ref-123 class=n-a></a><span class=label>123. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726861250"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25947e4331 class=n-a></a>Kotschy A, Szlavik Z, Murray J, <i> et al.</i>: The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. <i>Nature.</i> 2016; <b>538</b>(7626): 477–82. <a target=xrefwindow id=d25947e4342 href="http://www.ncbi.nlm.nih.gov/pubmed/27760111">PubMed Abstract </a> | <a target=xrefwindow id=d25947e4345 href="http://dx.doi.org/10.1038/nature19830">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726861250">F1000 Recommendation</a></span></li><li><a name=ref-124 class=n-a></a><span class=label>124. </span>&nbsp;<span class=citation><a name=d25947e4358 class=n-a></a>Lincoln SE, Yang S, Cline MS, <i> et al.</i>: Consistency of <i>BRCA1</i> and <i>BRCA2</i> Variant Classifications Among Clinical Diagnostic Laboratories. <i>JCO Precis Oncol.</i> 2017; <b>1</b>. <a target=xrefwindow id=d25947e4376 href="http://www.ncbi.nlm.nih.gov/pubmed/28782058">PubMed Abstract </a> | <a target=xrefwindow id=d25947e4379 href="http://dx.doi.org/10.1200/PO.16.00020">Publisher Full Text </a> | <a target=xrefwindow id=d25947e4382 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5542009">Free Full Text </a></span></li><li><a name=ref-125 class=n-a></a><span class=label>125. </span>&nbsp;<span class=citation><a name=d25947e4391 class=n-a></a>Bose P, Simmons GL, Grant S: Cyclin-dependent kinase inhibitor therapy for hematologic malignancies. <i>Expert Opin Investig Drugs.</i> 2013; <b>22</b>(6): 723–38. <a target=xrefwindow id=d25947e4399 href="http://www.ncbi.nlm.nih.gov/pubmed/23647051">PubMed Abstract </a> | <a target=xrefwindow id=d25947e4402 href="http://dx.doi.org/10.1517/13543784.2013.789859">Publisher Full Text </a> | <a target=xrefwindow id=d25947e4405 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4039040">Free Full Text </a></span></li><li><a name=ref-126 class=n-a></a><span class=label>126. </span>&nbsp;<span class=citation><a name=d25947e4415 class=n-a></a>Byrd JC, Lin TS, Dalton JT, <i> et al.</i>: Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. <i>Blood.</i> 2007; <b>109</b>(2): 399–404. <a target=xrefwindow id=d25947e4426 href="http://www.ncbi.nlm.nih.gov/pubmed/17003373">PubMed Abstract </a> | <a target=xrefwindow id=d25947e4429 href="http://dx.doi.org/10.1182/blood-2006-05-020735">Publisher Full Text </a> | <a target=xrefwindow id=d25947e4433 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1785084">Free Full Text </a></span></li><li><a name=ref-127 class=n-a></a><span class=label>127. </span>&nbsp;<span class=citation><a name=d25947e4442 class=n-a></a>Flynn J, Jones J, Johnson AJ, <i> et al.</i>: Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia. <i>Leukemia.</i> 2015; <b>29</b>(7): 1524–9. <a target=xrefwindow id=d25947e4453 href="http://www.ncbi.nlm.nih.gov/pubmed/25708835">PubMed Abstract </a> | <a target=xrefwindow id=d25947e4456 href="http://dx.doi.org/10.1038/leu.2015.31">Publisher Full Text </a> | <a target=xrefwindow id=d25947e4460 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4551390">Free Full Text </a></span></li><li><a name=ref-128 class=n-a></a><span class=label>128. </span>&nbsp;<span class=citation><a name=d25947e4469 class=n-a></a>Galletti G, Scielzo C, Barbaglio F, <i> et al.</i>: Targeting Macrophages Sensitizes Chronic Lymphocytic Leukemia to Apoptosis and Inhibits Disease Progression. <i>Cell Rep.</i> 2016; <b>14</b>(7): 1748–60. <a target=xrefwindow id=d25947e4480 href="http://www.ncbi.nlm.nih.gov/pubmed/26876171">PubMed Abstract </a> | <a target=xrefwindow id=d25947e4483 href="http://dx.doi.org/10.1016/j.celrep.2016.01.042">Publisher Full Text </a></span></li><li><a name=ref-129 class=n-a></a><span class=label>129. </span>&nbsp;<span class=citation><a name=d25947e4492 class=n-a></a>van Attekum MHA, Terpstra S, Slinger E, <i> et al.</i>: Macrophages confer survival signals via CCR1-dependent translational MCL-1 induction in chronic lymphocytic leukemia. <i>Oncogene.</i> 2017; <b>36</b>(26): 3651–60. <a target=xrefwindow id=d25947e4503 href="http://www.ncbi.nlm.nih.gov/pubmed/28192408">PubMed Abstract </a> | <a target=xrefwindow id=d25947e4506 href="http://dx.doi.org/10.1038/onc.2016.515">Publisher Full Text </a> | <a target=xrefwindow id=d25947e4510 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5584520">Free Full Text </a></span></li><li><a name=ref-130 class=n-a></a><span class=label>130. </span>&nbsp;<span class=citation><a name=d25947e4519 class=n-a></a>Tap WD, Wainberg ZA, Anthony SP, <i> et al.</i>: Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. <i>N Engl J Med.</i> 2015; <b>373</b>(5): 428–37. <a target=xrefwindow id=d25947e4530 href="http://www.ncbi.nlm.nih.gov/pubmed/26222558">PubMed Abstract </a> | <a target=xrefwindow id=d25947e4533 href="http://dx.doi.org/10.1056/NEJMoa1411366">Publisher Full Text </a></span></li><li><a name=ref-131 class=n-a></a><span class=label>131. </span>&nbsp;<span class=citation><a name=d25947e4542 class=n-a></a>Strachan DC, Ruffell B, Oei Y, <i> et al.</i>: CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8<sup>+</sup> T cells. <i>Oncoimmunology.</i> 2013; <b>2</b>(12): e26968. <a target=xrefwindow id=d25947e4556 href="http://www.ncbi.nlm.nih.gov/pubmed/24498562">PubMed Abstract </a> | <a target=xrefwindow id=d25947e4560 href="http://dx.doi.org/10.4161/onci.26968">Publisher Full Text </a> | <a target=xrefwindow id=d25947e4563 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3902121">Free Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 31 Oct 2017</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/6-1924&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/6-1924&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA<br/> <sup>2</sup> Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA<br/> <p> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/6-1924/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 31 Oct 2017, 6:1924 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.11618.1">https://doi.org/10.12688/f1000research.11618.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2017 Bose P and Gandhi V. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=12549 data-id=11618 data-downloads="" data-views="" data-scholar="10.12688/f1000research.11618.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/6-1924/v1/pdf?article_uuid=50d611e1-a46a-4d46-a4cf-99a544699dcb" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.11618.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Bose P and Gandhi V. Recent therapeutic advances in chronic lymphocytic leukemia [version 1; peer review: 2 approved] <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):1924 (<a href="https://doi.org/10.12688/f1000research.11618.1" target=_blank>https://doi.org/10.12688/f1000research.11618.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=11618 id=mobile-track-article-signin-11618 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/11618?target=/articles/6-1924"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=12549 /> <input name=articleId type=hidden value=11618 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Jacqueline Barrientos</strong>, CLL Research and Treatment Program, Department of Internal Medicine, Hofstra Northwell School of Medicine, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Emili Montserrat</strong>, Department of Hematology Hospital Clinic, University of Barcelona, Spain </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 31 Oct 2017</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/6-1924&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/6-1924&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=27268-27168></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=27267-27169></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/6-1924/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>31 Oct 17</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Jacqueline Barrientos</strong>, CLL Research and Treatment Program, Department of Internal Medicine, Hofstra Northwell School of Medicine, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Emili Montserrat</strong>, Department of Hematology Hospital Clinic, University of Barcelona, Spain </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/6-1924&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/6-1924/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Recent therapeutic advances in chronic lymphocytic...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/6-1924/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/6-1924/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/6-1924/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Bose P and Gandhi V');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/6-1924/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/6-1924",
            templates : {
                twitter : "Recent therapeutic advances in chronic lymphocytic leukemia. Bose P and Gandhi V, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/6-1924/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Recent therapeutic advances in chronic lymphocytic leukemia", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Recent therapeutic advances in chronic lymphocytic leukemia", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/11618/12549")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "12549");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "27168": 0,
                           "27169": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "e547ecdf-9324-4d20-90b6-8207b16a4b0d";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-1924.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-1924.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-1924.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/6-1924.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/6-1924.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>